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In the practice of human genetics, there is a gulf between the study of 
Mendelian and complex inheritance. When diagnosis of families affected by presumed 
monogenic syndromes is undertaken by genomic sequencing, these families are typically 
considered to have been solved only when a single gene or variant showing apparently 
Mendelian inheritance is discovered. However, about half of such families remain 
unexplained through this approach. On the other hand, common regulatory variants 
conferring low risk of disease still predominate our understanding of individual disease 
risk in complex disorders, despite rapidly increasing access to rare variant genotypes 
through sequencing. This dissertation utilizes primarily exome sequencing across several 
developmental disorders (having different levels of genetic complexity) to investigate 
how to best use an individual’s combination of rare and common variants to explain 
genetic risk, phenotypic heterogeneity, and the molecular bases of disorders ranging 
from those presumed to be monogenic to those known to be highly complex. 
The study described in Chapter 2 addresses putatively monogenic syndromes, 
where we used exome sequencing of four probands having syndromic 
neurodevelopmental disorders from an Israeli-Arab founder population to diagnose 
recessive and dominant disorders, highlighting the need to consider diverse modes of 
inheritance and phenotypic heterogeneity. In the study described in Chapter 3, we 
address the case of a relatively tractable multifactorial disorder, Hirschsprung disease. 
We identified new risk genes in a relatively small cohort (190 probands) by combining 
statistical genetics with functional assays. We then used both known and novel genes 
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and loci for quantifying individual genetic risk for Hirschsprung disease, on the basis of 
common and rare variant genotypes. In the fourth and final chapter, we address the 
case of a highly complex and heterogeneous disorder, autism spectrum disorder. We 
investigated the basis for exceptionally high genetic risk in 99 families having multiple 
females affected with autism, showing their risk originates in part from the same genes 
responsible for de novo risk in simplex families. However lack of significant results in 
gene discovery indicates that functional and external validation is needed for definitive 
gene finding even in this cohort characterized by high genetic risk. 
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Chapter 1: Introduction 
The focus of this dissertation is to understand the utility of exome sequencing for 
gene and variant identification in three classes of neurodevelopmental disorders – a 
putatively monogenic syndrome, a relatively tractable multifactorial disorder for which 
some major genetic risk factors are known, and a highly complex and etiologically 
heterogeneous multifactorial disorder for which little genetic risk has been explained. 
To address the case of monogenic syndromes, I present gene discovery using exome 
sequencing of probands in four syndromic neurodevelopmental disorders within an 
Israeli-Arab founder population where a single gene and single variant is expected. To 
address the case of a relatively tractable multifactorial disorder, I present our work on 
identification of new risk genes and the use of both known and new genes and loci for 
quantifying individual genetic risk for Hirschsprung disease, where both multiple genes 
and multiple variants are expected. To address the case of a highly complex and 
heterogeneous disorder, I investigate genes underlying the exceptionally high genetic 
risk in families with multiple females affected with autism, a neurodevelopmental 
disorder with high genetic complexity involving rare and common variation in hundreds 
of genes. Thus, this dissertation addresses the challenges inherent in exome and or 
genome sequencing from monogenic to highly complex disorders. 
For any genetic disorder, we must ultimately be able to accurately identify 
genetic risk factors, predict their genotypic risk in the broader population, and 
understand their role in the disease process. While identification of disease associated 
genes without a corresponding understanding of their contribution to disease risk in the 
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general population can aid our understanding of their role in the disease process, 
accurate estimation of the risk they impart is needed to achieve more complete 
molecular diagnoses, for risk prediction in the general population, and for 
understanding the relative contributions of different genes to disease etiology in order 
to better inform investigations of the disease process. 
For monogenic disorders, in which molecular diagnosis is comparatively 
straightforward, identification of disease-causing variation continues to present many 
difficulties (Chong et al., 2015). Firstly, there are technical issues which can frustrate the 
accurate identification of coding variation underlying monogenic disorders. Even when 
the whole genome is accurately sequenced, our lack of a thorough understanding of 
genomic function leads us to rely on imperfect genomic annotations that exclude some 
causal variants from consideration, especially if they cause disease through a 
hypomorphic, gain of function, or noncoding regulatory mechanism (Eilbeck et al., 
2017). In practice, the whole genome sequence of an individual, moreover, is never 
known perfectly or completely. For example, variants may not be detected or accurately 
identified using sequencing; somatic mosaic variants that often underlie dominant 
disorders are especially difficult to accurately identify. Moreover, the identification of 
monogenic disorders often relies heavily upon careful phenotyping to narrow down 
potential causative genes, which becomes increasingly difficult when many identical or 
very similar phenotypes can be caused by different genetic disorders. Narrowing down 
the cause of a disorder also becomes more difficult when there is only one affected 
individual in a family, making determination of the inheritance pattern more difficult. 
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Perhaps the greatest complication in identifying monogenic disorders is that they may 
not follow a strictly Mendelian inheritance pattern. 
While there are some variants in some genes that result in completely penetrant 
disorders, there are many “monogenic” disease alleles showing incomplete penetrance 
and variably expressivity. Evidence of this is the presence of many apparently disease-
causing genotypes within populations of healthy individuals (Xue et al., 2012). Further, a 
genetic variant may show Mendelian inheritance on one genetic background but 
complex patterns in another. Even within families, clinically affected individuals can 
encompass a wide phenotypic spectrum (Chong et al., 2015), with some mutation 
bearers not being clinically affected. Ascertainment biases owing to our choosing only 
the ‘Mendelian’ cases to examine may contribute to a bias in which we discount 
exceptions to Mendelian inheritance (Chakravarti, 2011). Therefore, there is the distinct 
possibility that as we observe more and more individuals, especially those not 
ascertained on the basis of segregation in families, we may recognize that many 
Mendelian disorders are more complex than they initially appeared. Thus, addressing 
the role of sequencing for gene discovery in complex disorders is the main problem. 
There are a few key factors that contribute to incomplete penetrance and 
variable expressivity of disease genotypes. First, even within genes that show Mendelian 
inheritance, there can be many variants of lesser effect that may result in increased 
disease risk but are not recognized. Interpreting the pathogenicity of missense alleles, 
for example, is a common problem which does not always have a yes or no answer, 
whether one is trying to explain a phenotype or trying to determine genetic risk for the 
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purpose of counselling. Second, variation in one or many genes may modify the 
presentation of monogenic diseases, as is the case with cystic fibrosis (Drumm et al., 
2005), or may even shift the phenotypic spectrum of a disorder from a disease to a non-
disease state. Third, measurable environmental factors are often important modifiers of 
phenotype. Fourth and lastly, inherent developmental stochasticity can have important 
roles in determining an individual’s ultimate phenotype. Such stochasticity can result 
from somatic mosaicism of de novo variation observable in an individual, or stochastic 
gene expression and post-transcriptional regulation early in development through gene 
regulatory networks (Honegger & de Bivort, 2018). Appreciation of the factors that 
affect penetrance and expressivity of genotypes can have important consequences for 
genetic risk prediction and for understanding which aspects of the disease process 
might be targeted to either prevent or treat the disorder. 
In the first study I present here, that of putatively consanguineous patients from 
an Israeli Arab founder population with syndromic disorders, we expect that many of 
the variant interpretation difficulties I have mentioned will be mollified. In such 
populations, decreased genetic and environmental variation are expected to make 
disease genotypes more penetrant because the genetic background is more uniform, 
and, in such families, high rates of homozygosity are expected to result in a 
preponderance of homozygous recessive disease, simplifying the variant filtering 
process by allowing the gene search to be limited to autozygous regions. High diagnostic 
yields that have been achieved for Mendelian disorders in consanguineous populations 
result primarily from searches for recessive genes only, which have resulted in a 
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diagnostic yield of 70% (Beaulieu et al., 2014) compared to around 50% in outbred 
populations (Chong et al., 2015) where all modes of inheritance were considered. 
However, for families in endogamous communities without known proximal 
consanguinity it is important to consider non-recessive modes of inheritance as well. 
Eaton et al. (2020) found that only 15% of genetic diagnoses for simplex cases 
originating from an endogamous population had a confirmed recessive basis whereas 
46% of diagnoses resulted from de novo variation; however, recessive diagnoses were 
much more common in multiplex families and recessive inheritance accounted for 75% 
of all diagnoses for families from endogamous populations. These results highlight the 
importance of considering additional modes of inheritance for presumed 
consanguineous populations, yet Eaton et al. did not consider dominant etiologies 
resulting from incomplete penetrance in parents. 
Each of the four patients we studied had a different developmental disorder. 
Three patients had severe developmental delay in combination with other syndromic 
features, and one patient had an ectodermal dysplasia with mild developmental delay. 
In contrast to previous studies of such families, we considered all monogenic modes of 
inheritance for each patient, including incompletely penetrant dominant mutations, in 
order to determine which etiologies could contribute to the high burden of 
neurodevelopmental disorders in such populations. For three of the four genes, 
syndromic features greatly aided gene finding. Our findings, especially of an apparent 
dominant disorder with reduced penetrance in one proband, highlight the benefit of 
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considering more than recessive or purely Mendelian inheritance-based explanations 
even for syndromic developmental disorders in founder populations. 
The importance of appreciating greater complexity with respect to Mendelian 
disorders is further demonstrated by the case of congenital nicotinamide adenine 
dinucleotide (NAD) deficiency disorder. It is caused by biallelic loss of function mutations 
in three genes encoding essential enzymes in the kynurenine NAD synthesis pathway, 
resulting in a combination of vertebral, cardiac, renal, and limb defects (VCRL) or in fetal 
loss (Shi et al., 2017; Szot et al., 2020). Cuny et al. (2020) showed through studies in 
mice that a variety of other factors influencing primarily maternal NAD biosynthesis can 
impact fetal NAD levels so as to result in varying incidence and extent of congenital 
malformation in a manner dependent on genotype and environment. These risk factors 
include limited maternal intake of the NAD precursors tryptophan and niacin, hypoxia 
(which results in decreased oxygenase-dependent synthesis of NAD from tryptophan), 
and potentially maternal and fetal genotype for 17 genes involved in the NAD 
biosynthesis pathway that could affect fetal NAD levels. The impact of these new 
environmental and genetic risk factors suggests that NAD deficiency may be the cause 
of a number of idiopathic congenital malformations and could allow for nutritional 
intervention for those mothers who harbor a genotype predisposing to NAD deficiency. 
While such a clear nutritional intervention will likely be rare for genetic disorders, NAD 
deficiency demonstrates how we may be missing many variants with reduced 
penetrance and how those variants can be discovered not through testing association 
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for every genomic locus for every disorder but through seeking to better understand the 
biology of seemingly Mendelian disorders. 
The second disease studied as part of this dissertation, Hirschsprung disease 
(HSCR), is also one in which putatively Mendelian forms have led to major advances in 
understanding of HSCR risk in the general population. HSCR is a neurodevelopmental 
disorder of the enteric nervous system, in which the more severe forms are 
characterized by autosomal dominant inheritance and the less severe forms by recessive 
or multifactorial inheritance (characterized by high recurrence risk in the absence of 
major risk genes), but the variants associated with both forms have incomplete 
penetrance (Badner et al., 1990). Prior to the study presented here, 17 genes and 
several chromosomal disorders had known associations with HSCR; chief among the 
associated genes are those coding for the receptor tyrosine kinase RET (Edery et al., 
1994), reduction of which constitutes a dominant form with reduced penetrance, and 
the G-protein-coupled receptor EDNRB (Puffenberger et al., 1994). EDNRB was initially 
identified by linkage-cum-association, resulting from a high frequency mutation in a 
founder population, where EDNRB had combined with other genetic risk factors to 
cause what was initially assumed to be a recessive form of HSCR in affected families 
(Puffenberger et al., 1994). The high frequency of the variants implies that affecteds 
have both heterozygous and homozygous variants.  EDNRB is, therefore, a great 
example of why we should not discount the possibility of non-recessive disease in 
founder populations. In addition to these single genes and chromosomal disorders, four 
noncoding variants together confer risk that can vary by 30 fold with increasing risk 
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allele dosage (Kapoor et al., 2015). In the study I present here we combined genotyping 
of these common variants, rare coding variants in known and novel genes, and genomic 
copy number variation in 190 individuals to show that genotype specific odds ratios for 
HSCR vary by a factor of 67, allowing for HSCR genetic risk stratification on the basis of 
genes discovered through a combination of linkage, association, and sequence-based 
analyses. 
HSCR represents a case in which risk factors identified through a combination of 
Mendelian and complex disease genetics collectively translate to a major impact on 
individual genetic risk. Autism spectrum disorder (ASD), on the other hand, represents a 
case in which there are many known risk genes but where the contributions of these 
genes to autism liability in the population are not well understood, despite the high 
heritability of ASD. This is in part because genetic studies of autism have focused on 
gene discovery through de novo mutations in families with only one affected individual 
(Iossifov et al., 2014; O’Roak et al., 2012; Sanders et al., 2012, 2015; Satterstrom et al., 
2020). Such mutations are non-recurrent with low genetic risk, while the high 
heritability of autism results from inherited variation.  
We, in contrast, chose to exome sequence 99 families with multiple females 
severely affected with autism, which constitute a group of families with exceptionally 
high genetic risk on the basis of female sex, severity of the disorder, and familial disease 
(Turner et al., 2015). This approach to autism genetics assumes that ASD in these 
families results from a greater burden of rare inherited protein coding variation than in 
other autism families. This is based in part on the positive relationship between 
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membership in the same three recurrence risk classes represented by FEMFs (female 
sex, severe disease, and familial disease) and the proportion of individuals with coding 
mutations discovered in the major risk gene (RET) in HSCR (Emison et al., 2010). A 
preliminary study in fewer female containing multiplex autism families identified 
CTNND2, and suggested CYFIP1 as autism risk genes, serving as evidence of this 
increased burden of coding variants (Turner et al., 2015). We confirmed that FEMFs are 
enriched for putatively damaging coding variation among 28 high confidence autism 
genes identified through excess de novo variation in simplex families (Sanders et al., 
2015), confirming that there are commonalities in etiology between those de novo 
contributions to autism and inherited genetic risk in FEMFs, though it is clear that 
functional follow up on genetic findings is necessary to confirm our genetic findings in 
families. 
Mendelian disorders with syndromic presentations are overrepresented in 
human genetics research and especially in clinical genomic sequencing studies because 
the high penetrance of such disorders increases our power to discover new genes that 
have relatively simple clinical interpretations. However, in studying such disorders, we 
must keep in mind that genes discovered in collections of a few exceptional Mendelian 
families will ultimately need to be interpreted in everyone. As genomic sequencing 
becomes prevalent, we need to look at the impact of variants in representative, 
heterogeneous populations to be able to predict genetic risk in individuals accurately, 
even for variants that have large impacts on risk in discovery populations. Ultimately, if 
we wish to explain genetic risk in families, it is important to be able to query the impact 
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of genetic variants on risk across individuals having different genetic backgrounds, 
different combinations of rare risk alleles, sex, family history, and other underlying 
disease susceptibilities, which highlights the importance of thoroughly phenotyped 




Chapter 2: Identification of Mendelian disease Genes in an 
Israeli-Arab Community Characterized by Consanguinity 
 
2.1 Chapter Introduction 
 
Clinical exome sequencing in families with Mendelian disorders is successful 
roughly half of the time (Chong et al., 2015). However diagnostic yield of clinical exome 
sequencing varies from 8 to 70% based on the inheritance of phenotypes being studied 
and the sequencing regime applied (Wright et al., 2018). The highest diagnostic yield for 
exome sequencing, 70%, has been reported for individuals from consanguineous unions 
or from endogamous founder populations (Beaulieu et al., 2014). The gene finding 
approach used to achieve this high diagnostic yield was based on finding of recessive 
genes only. Interestingly, though 11% of the successes in recessive gene finding in the 
study by Beaulieu et al. resulted from compound heterozygote genotypes rather than 
from autozygous variants, non-recessive modes of inheritance were not examined. 
Thus, even many cases of recessive traits even in inbred families do not result from 
identity by descent. In the case of families from endogamous communities but without 
known proximal consanguinity, it is especially important to consider non-recessive 
modes of inheritance. Eaton et al. (2020) found that only 15% of genetic diagnoses for 
simplex cases originating from an endogamous population had a confirmed recessive 
basis for disease, with 46% of diagnoses resulting from de novo variation. Not 
unexpectedly, when multiplex and simplex families were taken together, however, 
recessive inheritance constituted 75% of all diagnoses for families with presumed 
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consanguinity. These results highlight the importance of considering additional modes 
of inheritance for presumed consanguineous families, especially for simplex cases. 
Eaton et al. did not consider dominant etiologies resulting from incomplete penetrance 
in parents, which should also make substantial contributions to disease in endogamous 
populations just as they do in all populations. In this study, our goal was to assess the 
results of exome sequencing in an endogamous founder population by looking for all 
highly penetrant disease alleles, when no autozygous disease gene variant was 
identified. We expect that consideration of additional modes of inheritance will 
ultimately increase diagnostic yield, although it introduces new challenges in 
interpretation. 
In order to test this more complete approach to exome sequencing 
analysisdisease gene discovery in families from an endogamous founder population, we 
analyzed exome sequencing from four simplex developmental disorder probands 
originating from an Israeli-Arab founder population. Each of the four patients we 
studied had a different developmental disorder with syndromic features, which we 
utilized, in combination with exome sequencing, to determine their molecular genetic 
diagnosesbases. Through this study, we hoped to both provide diagnoses for patients, to 
determine which etiologies contribute to the high burden of neurodevelopmental 
disorders in founder populations, and to evaluate the potential effectiveness of 
proband-only exome sequencing for diagnosis in a founder population. Here, I present 
the general exome sequencing methods I used for diagnosis, followed by each of the 
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four cases as a separate case studiesy, and I end with a brief discussion of our complete 
findings across the four cases. 
2.2 Exome Sequencing and Analysis Methods 
 
For each of the four patients, exonic sequences were enriched using Nextera 
Rapid Capture Expanded Exome Kits (Illumina, San Diego, CA). Sequencing was 
performed on the HiSeq2500 (Illumina, San Diego) instrument with 100 bp paired-end 
reads. Read alignment to reference genome hg19 (GRCh37) was performed using the 
Burrows–Wheeler Aligner (Heng Li, 2013) and variant calling was performed using 
Samtools (Heng Li et al., 2009). Annotation of variants was performed using ANNOVAR 
(Wang et al., 2010) in combination with in-house scripts. 
Following alignment and variant calling, we removed variants with a PHRED 
quality score less than 30 or coverage less than 10 reads to exclude low quality variant 
calls. Following variant annotation, we filtered variants to only those with an allele 
frequency less than 1% in 1000 Genomes (www.1000Genomes.org) and the Exome 
Sequencing Project (http://evs.gs.washington.edu/EVS/) databases, and which were 
considered to be damaging based on their predicted genic impact and phylogenetic 
conservation. For single nucleotide variants (SNVs), we retained splice site, stop-gain, 
stop-loss, and non-synonymous variants deemed most likely to affect protein function 
(i.e., phyloP or GERP++ phylogenic conservation score greater than 4 and polyPhen 
structural prediction of ‘damaging’). We also examined small insertion deletion (indel)  
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variants, which were filtered by SIFT Indel (Hu & Ng, 2013) for those predicted as 
damaging with confidence score greater than 0.8.  
When the disorders were considered likely to be recessive, based on known 
parental consanguinity, we further filtered to include only homozygous and compound 
heterozygous variants that were - in a homozygous state in the exomes of other 
individuals from the same population who had different developmental disorders. 
However, we went on to investigate other modes of inheritance if a diagnosis was not 
obtained under the assumption of recessive inheritance. For the one family where there 
was no known history of consanguinity, we did not include this recessive filtering step, 
instead relying more heavily on clinical features in order to narrow down candidate 
genes. 
2.3 Case 1: A PIGN Mutation Responsible for Multiple Congenital 
Anomalies–Hypotonia–Seizures Syndrome 1 (MCAHS1) - reprinted with 




MCAHS1 (OMIM 614080) is an autosomal recessive disorder characterized by 
developmental delay, hypotonia and epilepsy, combined with multiple congenital 
anomalies owing to mutations in the PIGN gene (Maydan et al., 2011; Ohba et al., 2014). 
PIGN is one of more than 20 genes involved in the glycosylphosphatidylinositol (GPI) 
anchor biosyntheticsis pathway, of which PIGN protein controls the addition of 
phosphoethanolamine to the first mannose in GPI (Freeze et al., 2012; Hong et al., 
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1999). Mutations in PIGN, and seven additional genes involved in GPI biosynthesis, have 
been identified in individuals presenting with varied neurological abnormalities (Brady 
et al., 2014; Freeze et al., 2012; Hansen et al., 2013; Krawitz et al., 2013; Kvarnung et al., 
2013; Maydan et al., 2011; Ohba et al., 2014). We here report on a girl with MCAHS1 
who was born to consanguineous parents and harbors a novel homozygous novel 
c.755A>T PIGN mutation. Our family is the second consanguineous Israeli–Arab family, 
and the fourth family, reported to date with MCAHS1 resulting from a mutation in the 
PIGN gene (Brady et al., 2014; Maydan et al., 2011; Ohba et al., 2014). 
Proband Specific Methods: 
Sanger Sequencing: As a confirmation of exome sequencing results, sequence 
analysis of exon nine of PIGN, using genomic DNA from the patient, two healthy sisters, 
one healthy brother and their parents was performed by amplification of a 229 bp 
fragment containing the putative mutation deleterious variant identified through exome 
sequencing. The sense 5’-AAGCATTTCAGAAGTTACTG-3’ and the antisense 5’-
AAGACATCTAATCCTCTCAA-3’ primers were used under the following PCR conditions for 
DNA amplification: denaturation at 94°C for 5 min; 35 subsequent amplification cycles 
performed at 94°C for 30 sec, at 55°C for 45 sec and at 72°C for 30 sec; and followed by 
another 72°C for 5 min. The sequencing reaction was performed using the BigDdye 
terminator kit and analyzed by the ABI PRISM 3130xl Genetic Analyzer (Applied 
Biosystems, Warrington, UK), according to the manufacturer’s instructions. 
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Flow Cytometry (FC) Analysis: We examined the effect of the c.755A>T mutation 
in PIGN on the surface expression of GPI-anchored proteins by staining granulocyte cells 
with fluorescently-labeled inactive toxin aerolysin (FLAER–ALEXA) (CEDARLANE, 
Burlington, NC), and mouse antidecay accelerating factors CD16,CD18, CD24, and CD45 
antibodies (BD Biosciences, Franklin Lakes, NJ). The antibodies against the following 
were FITC, PE, APC, and PerCP fluorescently labeled, and used in comprehensive four-
color multiparameter Flow Cytometric Analysis on a BD FACSCalibur (BD Biosciences). 
Clinical Summary: 
 
Family history: The parents of our proband are first cousins of Israeli–Arab origin. 
They have two sons and two daughters who are healthy. They had two prior 
spontaneous abortions and reported another male baby, who died at age of 12 days, 
following the diagnosis of diaphragmatic hernia (no further details are available). The 
mother had a brother who died during his 1st year of life but no further details are 
available. Otherwise, the family history is unremarkable (Figure 1). 
Clinical description of the proband: The pregnancy was normal, with no known 
teratogenic exposure; the mother was 32 years old. The proband (IV4 in Figure 1) was 
born at term with normal birth weight of 3300 g. Weakness of muscles was noticed at 
age four months. At age nine months a metabolic work-up that included complete blood 
count, serum routine chemistry, glucose, lactate, ammonia, biotinidase, creatine kinase, 
acylcarnitines, amino acids, very long chain fatty acids, and isoelectric focusing of 
transferrins and urinary organic acids profiles were all normal. Cerebrospinal fluid 
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analysis for cells, glucose, protein, lactate, and amino acids were normal. Enzymatic 
assays in white blood cells of enzyme activities for various lysosomal diseases including 
GM1 and GM2 deficiency, Krabbe, and MLD were negative. Clinical examination showed 
hypotonia and dysmorphic features “reminiscent of Down syndrome” (Figure 2A,B). At 
age six months the 1st seizure was noticed; at age 10 months the diagnoses of 
convulsions, developmental delay, and hypotonia were recorded. EEG analysis revealed 
epileptiformic bursts. Brain MRI at nine months revealed widening of the sub-
arachnoidal space in the frontal and temporal lobes, the lateral ventricles widths being 
enlarged to 12mm. These findings were interpreted as brain atrophy. Echocardiography 
and ophthalmological examination were normal. Peripheral blood analysis of karyotype 
was 46,XX and normal, while FISH analyses specific to chromosomal regions 21q22.3 
and 9q34 were also normal. Cytogenetic array CGH yielded no known pathogenic copy 
number variants (CNV). 
Neurological assessment at age 13 months indicated DQ of 40, developmental 
delay and convulsions. At age 13 months she has had started to roll over, but there was 
no crawling, sitting or standing. Her weight and height were normal for her age. Her 
head circumference was 44.5 cm (10–25 percentile). Clinical examination revealed some 
unusual findings, including, brachycephaly, flat face, up-slanting palpebral fissures, 
synophrys, squint, large cheeks, small nose and mouth, relatively small ears (4 cm, 2nd 
percentile), hyperfolded and coarse helices, short neck, and dimples of elbows (Figure 
2A). There were no transverse creases of palms and the 5th fingers appeared almost 
normal. There was general mild hypoplasia of distal parts of all fingers. Brain MRI at age 
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23 months was interpreted as progressive white matter disease. At age five years there 
was only partial response to combined anti-convulsive therapy. She was not ambulant, 
had no speech, and she needed assistance with daily life activities including eating. 
Ophthalmological examination showed intermediate esotropia, nystagmus with vertical 
component, blepharitis, and normal fundi. Gastro-esophageal reflux was diagnosed. 
Clinical examination documented brachycephaly, some hypopigmented macules over 
the leg, open mouth, and drooling. There was good control of the head but hypotonia of 
the upper body with postural kyphosis while sitting. There was reduced strength of 
upper body, but in the lower body there was proximal weakness and increased tone 
distally. Tendon reflexes were mildly increased, with bilateral clonus. Her growth 
parameters were normal, with penciled eyebrows and epicanthal folds. The palpebral 
fissures were up-slanted, the eyes were deep set with nystagmus. We also noted a small 
nose and somewhat small auricles (5th percentile). Palm and finger length were normal, 
but the fingers appeared tapering in shape with hypoplastic fingernails; the thumb 
appeared unusually sharp (Figure 2C). There were prominent blood vessels over the 
skin, and there was indentation of the middle part of the chest. 
Results: 
 
Exome: After filtering exome sequencing data for a recessively inherited disease 
as described in the exome sequencing methods, 6 SNVs were retained across four genes 
(NBPF10, TEP1, CDC27, and PIGN). Only one gene, PIGN, is known to be associated with 
morbidities in OMIM database. The PIGN variant is a homozygous mutation located at 
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Chr18:59814254A>T, c.755A>T, p. D252V. We retained 24 indels in 24 different genes 
after filtering, but none of these genes had an apparent connection to the phenotype on 
the basis of reported morbidities in OMIM. 
Sanger Sequencing: The mutation was validated by Sanger sequencing which 
confirmed homozygosity for the c.755A>T variant in the proband IV4. The mother III1, 
father III2, and one sister IV3 were heterozygous for the same variant. One brother IV1 
and one sister IV2 were homozygous for the wild-type allele (Figure 3). 
Flow Cytometry: In order to examine the effect of the c.755A>T mutation on the 
function of PIGN, the surface expression of GPI-anchored proteins on granulocytes were 
analyzed by flow cytometry. Granulocytes were gated after staining with mouse anti-
CD45 PerCp to allow us to perform the FC analysis only on blood granulocytes (Figure 
4A). The overall expression of GPI-anchored proteins was significantly decreased to 53% 
of normal levels as revealed by FLAER expression on patient granulocytes (Figure 4B). 
CD24 and CD18 expression on granulocytes was decreased to 44% and 14% respectively 




The involvement of PIGN in MCAHS1 has been previously reported in two 
families. The first family, of Israeli-Arab origin, included seven affected individuals with a 
missense homozygous c.2126G>A (p.R709Q) mutation (Maydan et al., 2011). The 
second family, of Japanese origin, included two patients with compound heterozygosity 
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for c.808T>C (p.S270P) and c.963G>A variants (led to aberrant splicing, in which two 
mutant transcripts with premature stop codons p.E308Gfs*2 and p. A322Vfs*24 were 
generated) (Ohba et al., 2014). A third family of North African origin with a splicing 
homozygous mutation c.1574+1G>A in PIGN has been described with an intrauterine 
phenotype associated with diaphragmatic hernia (Brady et al., 2014). 
Here, we describe another family, the second of Israeli–Arab origin, with a PIGN 
mutation. The novel mutation c.755A>T that was detected in our proband was predicted 
to be “probably damaging” with a score of 1 (polyPhen-2), “deleterious” with a score of 
0 (SIFT) and disease causing with a P-value 1 (Mutation Taster). Contrary to the results 
published by Ohba (2014), the overall expression of GPI-anchored proteins in our 
patient blood granulocytes was significantly affected by the mutant PIGN compared to 
control samples, as revealed by the significant decrease in FLAER expression. Only CD24, 
but not CD16 and CD18, expression was drastically decreased on granulocytes from 
patients as compared to controls. Similar results for CD24, but not CD16, were reported 
previously (Ohba et al., 2014). These data support the conclusion that the novel 
mutation detected in our patient causes major damage to the GPI-anchored protein 
PIGN, thus leading to MCAHS1 in our patient. 
The girl we described has marked phenotypic overlap with the previously 
reported affected individuals, including developmental delay, hypotonia, epilepsy, and 
nystagmus (Maydan et al., 2011; Ohba et al., 2014). However, our proband did not 
present with congenital anomalies of the cardiac, urinary or gastrointestinal systems 
(excluding gastro-esophageal reflux) as in other patients. These phenotypic differences 
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could arise from allele specific effects, involvement of genetic modifiers or be 
developmental chance effects. The dysmorphic phenotype can be compared with only 
two of the families previously described, and overlap is present, in particular with 
respect to the unusual auricles and tapering fingers that were described in at least one 
individual (Maydan et al., 2011). 
In contrast, using exome sequencing, a homozygous splicing mutation 
c.1574+1G>A in the PIGN gene was identified in a fetus of consanguineous parents of 
North African descent, with multiple congenital anomalies including bilateral congenital 
diaphragmatic hernia (CDH) (Brady et al., 2014). These authors suggested that the 
increased severity of the phenotypic features represented by CDH in the tested fetus is 
due to the homozygous splicing mutation predicting a truncated protein, in comparison 
to reports of non-synonymous and splicing mutations which likely produce hypomorphic 
alleles. The family we describe had a male baby, who reportedly died at age of 12 days, 
following the diagnosis of diaphragmatic hernia. No DNA sample was available and thus 
mutation analysis could not be performed. Since the mutation detected in our patient is 
a nonsynonymous mutation, and speculating that the affected baby IV5 (Figure 1) in our 
family was homozygous for the same mutation, other hypotheses of environmental and 
genetic modification need to be considered. 
To date, mutations in eight genes (GIPA, GIPL, GIPM, GIPN, GIPO, GIPT, GIPV, and 
PGAP2) involved in the GPI biosynthesis pathway have been identified in humans. All 
the affected individuals involved share clinical features including seizures, cardiac 
defects, skeletal defects, and dysmorphic features (Almeida et al., 2006; Brady et al., 
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2014; Hansen et al., 2013; Horn et al., 2011; Johnston et al., 2012; Krawitz et al., 2010, 
2013; Maydan et al., 2011; Ng et al., 2012; Ohba et al., 2014). This suggests that some 
tissues are more sensitive than others to the loss of PIGN activity during embryonic 
development. This study strengthens the association between PIGN mutation and the 
intellectual disability–hypotonia–seizures syndrome, and expands the mutational 
spectrum found in this gene. 





Ectodermal dysplasia (ED) is a heterogeneous group of disorders characterized 
by lack or dysgenesis of at least two of ectodermal derivatives, including hair, nails, 
teeth, or sweat glands (Falk Kieri et al., 2014). Hypohidrotic ED (HED) is the most 
common form of ED and is characterized by a clinical triad of hypotrichosis (sparse hair), 
abnormal or missing teeth (anodontia or hypodontia) and deficient sweating 
(hypohidrosis or anhidrosis) (Falk Kieri et al., 2014). HED exhibits a variety of inheritance 
patterns.  X-linked HED (OMIM 3050100), the most common form, is caused by 
mutations in the ectodysplasin A (EDA) gene, while mutations in the EDA receptor 
(EDAR) and EDAR associated death domain (EDARADD) genes result in both autosomal 
dominant and  autosomal recessive forms (Cluzeau et al., 2011; Falk Kieri et al., 2014). 
Mutations in WNT10A are have also been found shown to be responsible for various 
autosomal recessive forms of ED (Cluzeau et al., 2011). Taken together, these four genes 
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The proband is a female and was referred to the genetics clinic at age 2.2 years 
due to lack of tooth development, sparse hair, and overheating episodes during physical 
exercise, suggestive of ectodermal dysplasia (ED). She was born by vaginal delivery at 41 
weeks gestation following an uneventful pregnancy, the second child of healthy, 
distantly related parents of Israeli-Arab ancestry. Her older brother was healthy. The 
family history was unremarkable. 
Physical examination revealed normal growth parameters: her weight and head 
circumference were 13 kg (between 25th and 50th percentiles) and 47 cm (25th 
percentile), respectively. She had sparse, light-colored, dry, fine scalp hair. Hypotrichosis 
was also noted in the eyebrows and eyelashes. Her skin was dry with patchy eczematous 
regions; neither fingernail nor toenail abnormalities were observed. She had slight 
coarsening of her facial features, including a wide nasal bridge, low inserted columella, 
everted vermilion of the lower lip, and large ear lobes. The philtrum was short and 
smooth, and the upper lip was thin. Additionally, deeply set eyes, narrow and upslanted 
palpebral fissures, and inflamed conjunctiva were present. She also had nasal speech, 
anodontia, triangular posterior notched cleft-palate and absent uvula. Borderline delay 
of motor milestones was present, but speech delay was more marked: at age 2.2 years, 
she spoke only a few words. 
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Follow-up examinations at age 4.5 years emphasized her distinctive facial 
features, which were more marked than in her previous examination, in particular her 
broad nose, thick lower lip, and hypertelorism. Additionally, premaxillar hypoplasia, 
short hard palate and a mild degree of glossoptosis were noted. Her nasal speech 
remained unchanged. Her growth parameters were normal, between the 25th and 50th 
percentiles (height - 105 cm, weight - 17 kg, head circumference - 48 cm). Prominently, 
there was a significant improvement of her dermal features, including scalp and 
eyebrow hair texture and density, and skin dryness. Yet fine scalp hair and mild 
hyperkeratosis of the palms with subtle hyperpigmentation over fingers joints were 
observed. Orthodontic assessment showed that she was missing all teeth but the two 
maxillary central incisors. Developmental milestones were within the normal range for 
her age. Chromosomal analysis revealed a normal female 46,XX karyotype. 
Results: 
 
After filtering variants under the assumption of recessive inheritance as 
described previously, 5 homozygous SNVs were retained across 5 genes (CDC27, EDAR, 
STEAP3, CBLB, and SLC22A1). Only EDAR and STEAP3 have listed morbidities in OMIM, 
and EDAR dysfunction is known to cause ectodermal dysplasia. There were also 7 
homozygous indels across 7 genes (OR52B4, SMPD1, ATN1, IFI27, C14orf180, TPSD1, 
and MUC20) of which SMPD1 and ATN1 have listed morbidities in OMIM, but none of 
these had an apparent connection to the clinical phenotype of the proband. The EDAR 
variant is a homozygous C>T mutation located at Chr2: 109546673 (c.77C>T, p. A26V). 
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The observed allele is unique in that it affects the canonical alanine of the signal peptide 
cleavage site, which might reduce or prevent cleavage of the peptide and formation of a 
mature EDAR protein (Z. Zhang & Henzel, 2004). To our knowledge, there have been no 
previously reported EDAR variants affecting this signal peptide. 
Discussion: 
 
The EDAR gene is 94.9 Kb in size, is located on chromosome 2q11-q13, and 
contains 12 exons (Cluzeau et al., 2011; Falk Kieri et al., 2014). EDAR protein is a 
member of the tumor necrosis factor (TNF) receptor family and is activated by its ligand 
EDA. EDAR uses EDARADD as an adaptor, via its death domain, to build an intracellular 
NFB signal transduction complex, which is crucial for normal development of 
ectodermal organs (Sadier et al., 2014). 22 causative mutations have been reported in 
the EDAR gene, compared to more than 100 mutations in the X-linked EDA gene (Azeem 
et al., 2009; Sadier et al., 2014). 
In addition to typical features of ED, our proband exhibited some phenotypic 
features that have not (to our knowledge) been described before in ED: these are 
posterior cleft palate and improved hair growth over time.  Cleft lip/palate is associated 
with ectodermal dysplasia in two well characterized genetic disorders: P-63 associated 
ectodermal dysplasias (EEC Syndrome, AEC Syndrome, Rapp-Hodgkin Syndrome, Limb-
mammary Syndrome) and Zlotogora-Ogur syndrome/CLEPD1 caused by mutations in 
PVRL1. Cleft palate has been infrequently described as a part of the clinical picture in ED 
in several case reports and series (Goyal et al., 2015; More et al., 2013). High-arched 
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palate, however, occurred in 68% of cases in one study of 19 patients with ectodermal 
dysplasia (More et al., 2013). Our patient may, therefore, represent an extreme form of 
the relatively common palatal malformations in ectodermal dysplasia. P63 associated 
ED, is a group of allelic disorders, caused by heterozygous mutations in the TP63 gene. It 
is characterized clinically by a mixture of HED and skeletal malformations, and, in a 
minority of cases, intellectual disability/mental retardation. P63 expression in the 
ectodermal surfaces of the limb buds, branchial arches and epidermal appendages in 
mouse embryos, supports its crucial role in their organogenesis and explains the 
phenotype of P63 associated ED (Ray et al., 2004; Yang et al., 1999). In addition several 
cases of non-syndromic cleft lip/palate have been found to be associated with TP63 
mutations, supporting the importance of P63 specifically in palatogenesis (Leoyklang et 
al., 2006; Scapoli et al., 2008). 
Zlotogora-Ogur syndrome/CLPED1(Cleft Lip/Palate-Ectodermal Dysplasia 
Syndrome) is an autosomal recessive condition, characterized clinically characterized by 
cleft lip/palate, hydrotic ED, developmental defects of the hands, and in some cases 
intellectual disability (Suzuki et al., 2000). It is caused by mutations in the PVRL1 gene, 
which encodes Nectin-1. Nectin-1 is part of the cadherin-based cell-to-cell adherens 
junctions through its binding to 1-afadin (Suzuki et al., 2000). In a developing mouse 
embryo model, PVRL1 mRNA was primarily expressed in the medial edge epithelium of 
the palatal shelves, the ectodermal component of tooth buds, and the skin surface 
epithelium (Suzuki et al., 2000), consistent with the phenotypic abnormalities 
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characteristic of this syndrome. PVRL1 has more recently been reported as a candidate 
gene in non-syndromic cleft lip/palate cases (Cheng et al., 2012). 
To our knowledge, this is the first report of cleft palate in an EDAR associated ED. 
However, one can imagine how lack of EDAR signaling might lead to cleft palate. The 
EDA-EDAR system, functions by stimulating NFB -mediated transcription of effectors or 
inhibitors of the Wnt (Kowalczyk-Quintas & Schneider, 2014; Y. Zhang et al., 2009), sonic 
hedgehog (SHH) (Kowalczyk-Quintas & Schneider, 2014), connective tissue growth 
factor (cTGF) (Pummila et al., 2007), fibroblast growth factor (FGF) (Kowalczyk-Quintas 
& Schneider, 2014), and transforming growth factor beta (TGFβ) (Kowalczyk-Quintas & 
Schneider, 2014) pathways, regulating interactions within and between epithelial and 
mesenchymal cells and tissues. These interplays interactions are relevant not only in 
appendage formation, but also to craniofacial organogenesis and palatogenesis. In a 
mouse model, failure of posterior muscle development led to posterior cleft palate, 
explained by secondary loss of TGFβ controlled WNT-β-catenin signaling activity (Iwata 
et al., 2014).  Bone morphogenic protein (BMP) is a protein of the Tumor Growth Factor 
(TGF) family, with hair and dental placode inhibiting effects (Kowalczyk-Quintas & 
Schneider, 2014; Pummila et al., 2007). The EDA-EDAR pathway inhibits BMP via 
expression of various proteins (e.g. connective tissue growth factor, CTGF), enabling 
placode activation and appendage formation (Pummila et al., 2007).  Loss of balance in 
the BMP pathway, leading to enhanced signaling, has been reported as a cause of 
complete cleft palate and delayed odontogenic differentiation (L. Li et al., 2013). In 
addition, absence of BMP inhibitors, such as CTGF and noggin, results in deregulation of 
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cell proliferation, excessive cell death, and changes in gene expression, leading to 
complete cleft palate (Goyal et al., 2015).  
Our proband exhibited marked improvement in her scalp and eyebrow hair 
growth, in terms of both texture and higher density, between her first and second 
evaluations, over the course of 2 years. Although pubertal growth of body hair tends to 
be normal in ED, spontaneous improvement of scalp and eyebrows hair growth seems 
rare, and, if found to be frequent in EDAR associated ED, might serve as a reassuring 
prognostic feature when counseling families.    
In summary, using exome sequencing, we found a novel homozygous missense 
mutation in the EDAR gene affecting the signal peptide cleavage site, which resulted in 
autosomal recessive HED with posterior cleft palate and improved scalp hair growth 
during childhood. We believe that this case provides further insight into the phenotypic 
spectrum and the natural history of EDAR associated ED, which may be under-
diagnosed. These findings support meticulous physical examination, and provide some 
positive prognosis with the possibility of spontaneous improvement over time, at least 
in some families. 
2.5 Case 3: An Interstitial 3p26 Deletion Resulting in Terminal 3p Deletion 




Terminal 3p deletion syndrome (OMIM 613792) has variable phenotypic 
associations, the most common of these being slow growth, developmental delay, 
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hypotonia, trigonocephaly, ptosis, hypertelorism, downslanting palpebral fissures, ear 
and nose abnormalities, and micrognathia. The syndrome is observed in individuals 
having heterozygous 3pter-p25, 3pter-p26 deletions, or large interstitial deletions 
affecting this terminal region, with greater severity and multiplicity of clinical features 
accompanying larger deletions (Shuib et al., 2009). While most individuals with 3p 
deletion syndrome have de novo deletions, some cases are inherited and there have 
been several cases in which individuals having large 3pter-p25 or 3pter-p26 deletions 
are apparently healthy and cognitively normal, though they may have severely affected 
family members with an identical deletion (Pohjola et al., 2010; Shuib et al., 2009; 
Takagishi et al., 2006; Knight et al., 1995). 
As increasing numbers of single gene disorders are discovered near the terminus 
of 3p, several dominant single gene disorders have been discovered which explain 
aspects of thise deletion syndrome, several of which can result in intellectual disability. 
Loss of SETD5 (Grozeva et al., 2014) and of BRPF1 (Mattioli et al., 2017) on 3p25 are 
individually associated with haploinsufficiency-based intellectual disability, yet many 
features of the syndrome may be observed in individuals with deletions of only 3p26, 
though with less severe cognitive manifestations. 
Clinical Summary: 
 
The proband’s parents are first cousins once removed. Retinitis pigmentosa, 
infertility, newborn death, and motor problems were reported within the extended 
family. During pregnancy, polyhydramnios, hypospadias, abnormally flexed right foot, 
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and a small penis were recorded. Penoscrotal hypospadias with chordee was diagnosed 
at birth. The proband had normal growth parameters at birth. At three months, the 
proband had moderate hypotonia and DD. At 5 months, the proband had surgery for 
craniosynostosis. 
Exonic sequencing of FGFR3, FGFR2, and FGFR1 were normal, as was sequencing 
of exon 1 of TWIST1 and RAB23. There were abnormal skeletal findings of the pelvis, 
with an abnormal opening of symphysis pubis. 
During a physical exam of the proband at two years, he was thin; his BMI was 2.5 
SD below the mean and he had little subdermal fat. His height was in the 10th percentile  
and his head circumference was in the 25th percentile. The proband had plagiocephaly, 
curly hair, hypertelorism, squint, high frontal hairline, and small teeth with caries.  He 
had wide, up-turned nares, retro-micrognathia, thin nasal bridge, and a short flat 
philtrum. He also had an abnormal left nipple. 
Results: 
 
After filtering exome sequencing for a recessively inherited disease as described 
in the exome sequencing methods, 8 variants were retained across 6 genes (NBPF10, 
MKI67, KLHL33, ZNF717, CDC27, AMER1). Only AMER1, which has listed morbidities in 
OMIM, and was a candidate but disruption of AMER1 would not result in the features 
observed in the proband. After filtering for indels, 19 variants across 19 genes were 
retained. Of these genes, 2 have listed morbidities in OMIM unrelated to those 
observed in the proband. 
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Array CGH was also performed on this proband, as part of his clinical genetic 
workup, in order to identify potentially pathogenic CNVs. A 3p26 deletion spanning 
chr3: 61,891 - 4,602,285 was discovered in the patient and array CGH on the patients 
parents showed that the deletion was inherited from the proband’s father. The deletion 
was further validated and resolved using the Plink PLINK homozygous run caller in 
combination with exome sequencing read depth. The CNV identified by array was thus 
extended slightly by way of exome sequencing to a 4.6 Mb deletion at chr3: 61,891 – 
4,683,606. Other individuals with 3p26 deletions have been reported as having a 3p 
deletion syndrome with comparable clinical features to those observed in the proband. 
3p26 deletions are also, however, sometimes observed in apparently healthy 
individuals. The deletion harbored by the proband results in loss of 10 protein-coding 
genes, two of which, LRRN1 and ITPR1, are intolerant of to single copy loss of function 
based on depletion of such variants in gnomAD (Karczewski et al., 2020). 
Discussion: 
 
The incompletely penetrant 3pter-p25 and p26 deletions that have been 
observed show that, while there are many apparently haploinsufficient genes on the 
terminus of 3p, none of them are completely penetrant. In the deletion present in the 
proband and in his apparently unaffected father, two apparently dominant disease 
genes are disrupted. 
ITPR1 encodes the inositol 1,4,5-triphosphate (IP3) receptor, which modulates 
intracellular calcium signaling, and is partially deleted in both the proband and the 
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father. The phenotype associated with loss of one copy of ITPR1 is fairly well defined 
and may have implications for the proband and other family members who may harbor 
this deletion. Heterozygous ITPR1 loss of function mutations may result in either 
congenital non-progressive (OMIM 117360) or progressive spinocerebellar ataxia 
(OMIM 609958). Non-progressive spinocerebellar ataxia is characterized by delayed 
motor development, hypotonia, cognitive delay and progressive ataxia, which may 
explain the hypotonia and developmental delay observed in the proband. It is possible 
that the same variant, on the father’s genetic background, might result in progressive 
spinocerebellar ataxia in the father, which can remain asymptomatic into adulthood. 
Thus loss of one copy of ITPR1 may well provide an explanation for motor problems 
reported within his extended family and may eventually manifest themselves in the 
father. 
LRRN1 encodes leucine-rich repeat neuronal protein 1, which is involved in the 
formation of the midbrain-hindbrain boundary in chick development (Tossell et al., 
2011). Loss of Lrrn1 in mice, moreover results in behavioral phenotypes 
(http://www.informatics.jax.org/marker/MGI:106038).  Loss of one copy of LRRN1 does 
not, however, have a well-defined human phenotype associated with it, as does ITPR1, 
though its important role in brain development and intolerance of variation indicates 
that loss of a single copy of LRRN1 may contribute to the features of terminal 3p 
deletion syndrome. 
Neither of the these two haploinsufficient genes provides a complete 
explanation for the features observed in the patient, which are likely influenced by loss 
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of the other eight genes deleted in the proband. However the apparent relevance of 
these two genes to the phenotype observed in the proband highlights the importance of 
evaluating large genomic deletions based on depletion of loss of function variation in 
healthy individuals, which can identify disease genes while allowing for incomplete 
penetrance. This approach is an improvement over past work to identify genes 
underlying terminal 3p deletion syndrome phenotypes based on the identification of 
completely penetrant critical regions which do not exist in an incompletely penetrant 
syndrome. 
2.6 Case 4: A missense mutation in the C-terminal zinc finger domain of 




Mowat-Wilson syndrome (OMIM 235730) is a moderate to severe ID syndrome 
characterized by a distinctive facial gestalt, often associated with microcephaly, 
epilepsy, corpus callosum agenesis, heart defects, urogenital malformations, and 
Hirschsprung’s disease (HSCR). Almost all features outside of the facial gestalt are 
incompletely penetrant, which is a complicating factor in accurate diagnosis of the 
disorder. HSCR was initially the basis of case ascertainment, but is now known to be only 
60% penetrant (Mowat, 2003). Mowat Wilson syndrome is caused by de novo mutations 
affecting one copy of the ZEB2 gene, which encodes a transcription factor having 
important roles in neural crest cell migration and corticogenesis (Seuntjens et al., 2009; 
Van de Putte et al., 2003). Almost all of the more than 180 reported pathogenic alleles 
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in Clinvar result in stop-gained mutations within or deletions of all or much of the gene, 
for which no functional protein is expected (Landrum et al., 2018), with only a handful 
or reported pathogenic missense changes. 
A recent study of the phenotypes and genotypes of 87 patients with Mowat-
Wilson syndrome, which included no cases harboring missense alleles in ZEB2, found 
that a less severe presentation was associated with cases where some functional 
protein was expected (Ivanovski et al., 2018). The study also found that the most 
consistent clinical associations with Mowat-Wilson syndrome are microcephaly and 
seizures. Seizures are a risk factor for regression of cognitive and motor skills in Mowat-
Wilson syndrome (Bonanni et al., 2017). 
Clinical Summary: 
 
The male proband was born to unrelated parents. The mother's nephew (a son 
of her sister, whose parents are not related) was reported to have DD and hypotonia. 
The father has a nephew with DD, whose parents are not related.  
Brain cysts were observed in the proband during pregnancy. His birth weight was 4.5 Kg 
(the mother is not diabetic). There was developmental delay, with appearance of speech 
that regressed. Febrile convulsions appeared at 2 years. 
In a physical examination at 3 years of age the proband was noted to share some 
dysmorphology with his father. At this time, the proband had no speech, a wide gait, 
stereotypic movements of his hands, and head banging. The proband had normal 
growth parameters with medial flare of the eyebrows, deep set eyes, epicanthal folds, 
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flattening of the nose, short philtrum, narrow palate, folded auricles, and prominent 
earlobes. The proband also had 5 hyperpigmented spots and tapering fingers. 
The proband had a normal metabolic work-up, normal brain magnetic resonance 
imaging and spectroscopy, normal electroencephalogram and normal brainstem evoked 
response audiometry. Cytogenetic array CGH yielded no known pathogenic copy 
number variant (CNV). TCF4 sequencing to screen for Pitt-Hopkins syndrome resulted in 
no pathogenic findings. 
Results: 
 
After filtering exome sequencing as described in the exome sequencing 
methods, without assuming recessive inheritance, 129 potentially pathogenic variants 
were retained across 81 genes.  Of these 81 genes, 17 have reported morbidities in 
OMIM. Of those 17 genes, each of which harbored a single heterozygous variant, three 
genes (ZEB2, IFIH1, and KCNT1) have reported phenotypes in OMIM that include 
developmental delay, though the presence of the IFIH1 and KCNT1 variants at low rates 
in healthy controls excluded their being sufficient for disease and, therefore, high-value 
candidates, in addition to a mismatch of the patients clinical features with those 
syndromes. The ZEB2 variant, on the other hand, is novel and Mowat-Wilson Syndrome 
is sufficient to explain all of the dysmorphic and pathologic features observed in the 
proband. The ZEB2 variant discovered is at Chr:145147446G>A, NM_014795 c.C3217T, 
p.H1073Y in ZEB2 and it was confirmed as de novo by Sanger sequencing in of the 
parents. After filtering, 64 potentially pathogenic indel variants were across 57 genes 
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were also retained. Of these genes, 6 have listed morbidities in OMIM, but none are 
consistent with the features of the proband. 
Amino acid position 1073 of ZEB2 encodes a histidine involved in zinc ion 
chelation within a highly conserved C-terminal zinc finger domain (C-ZF) 
(http://www.uniprot.org/uniprot/O60315). And it is only one residue away from 
another C-ZF variant previously reported to cause a relatively mild form of Mowatt-
Wilson syndrome (Ghoumid et al., 2013). There were three zinc-finger disrupting 
mutations reported in that study, all of which prevented binding of ZEB2 to the E-
cadherin promoter in vitro and rescued cranial morphology and neural crest cell 
proliferation in zebrafish morphants of a ZEB2 orthologue to varying degrees. 
Discussion: 
 
The three previously reported cases of relatively mild Mowat-Wilson syndrome, 
caused by missense mutations affecting ZEB2 C-ZF domains were caused by the 
mutations p.Tyr1055Cys, p.Ser1071Pro and p.His1045Arg (Ghoumid et al., 2013). Like 
the proband reported here, none of these cases had microcephaly and two of three had 
no observed brain anomalies. Only one of the three cases had observed brain 
anomalies, the patient having the p.His1045Arg mutation, and this mutation showed 
least rescue of zebrafish morphants, perhaps explaining the more severe phenotype of 
the patient, who also had hypospadias. The primary departure of the case reported 
here, from these other three other patients having ZEB2 C-ZF domain mutations, is his 
absence of speech (present to some extent in the three previously reported cases) , 
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which may be explained by seizure-associated regression, as the patient is reported to 
have had regression of early language development in addition to febrile convulsions. 
Only one of the three previously reported cases suffered from seizures and no 
regression was reported in any of the three cases. 
This work provides additional support for mild presentations of Mowat-Wilson 
syndrome associated with missense mutations affecting the ZEB2 C-ZF domains, in 
which few if any of the congenital malformations common to Mowat-Wilson syndrome 
are present, with the exception of facial dysmorphology. While the three previously 
described cases show superior language development compared to typical Mowat-
Wilson presentations, the case described here stands as an exception, suggesting that 
the phenotypic heterogeneity observed for individuals having a complete loss of one 
copy of ZEB2 is also the case for C-ZF domain mutations. 
2.7 Chapter Conclusions 
 
Two of the four probands investigated as part of this project have monogenic 
recessive disease resulting from autozygosity. Both sets of parents for these two 
probands have known relatedness to each otherare known relatives – the parents of the 
proband affected by MCAHS1 are first cousins and the parents of the proband affected 
by ectodermal dysplasia reported being distantly related. However, in another family 
where the proband’s parents are first cousins once removed, the proband’s condition is 
not explained by autozygous inheritance. A methodology that limited gene finding to 
only recessive modes of inheritance would therefore have missed the dominantly 
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inherited 3p terminal deletion syndrome in the proband, as would a methodology based 
on only recessive and de novo filtering, the approach used by Eaton et al. (2020). For the 
one patient we examined who did not have reported parental relatedness, however, the 
patient’s disorder is explained by de novo inheritance of Mowat-Wilson syndrome, 
consistent with the finding by Eaton et al. that nearly half of simplex cases originating 
from endogamous populations have de novo disorders. We had limited ability to identify 
de novo dominant mutations, as we performed proband-only exome sequencing, but 
the distinctive facial dysmorphology of Mowat-Wilson syndrome allowed us to narrow 
down the many potential disease-causing mutations more effectively than might be 
expected, which emphasizes the importance of combining exome sequencing with a 
thorough clinical description in order to identify the cause of an unknown 
developmental disorder. Additionally, trio-based exome sequencing should be routine. 
Our findings support the point made by Eaton et al. that, while endogamous 
founder populations are enriched for recessive disorders owing to increased 
autozygosity, looking for only recessive disease in these populations will result in 
missing the dominant disorders that also occur in all populations. Our finding of an 
incompletely penetrant large deletion also shows the importance of considering 
incompletely penetrant inheritance in combination with de novo inheritance as 
potential causes of disease in founder populations. Considering incompletely penetrant 
variants in founder populations is of special importance because we expect some rare 
damaging variants to exist at relatively high frequencies as a result of founder effects in 
these populations. Our case of terminal 3p deletion syndrome also highlights the 
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importance of considering copy number variation in the diagnosis of developmental 
disorders in founder populations.  
While endogamous populations are viewed as important for exome sequencing 
studies because of the expected high diagnostic yield resulting from increased 
autozygosity, these populations are subject, like other populations, to both de novo and 
inherited dominant disorders and gene finding must consider these hypotheses when a 
recessive disease sufficient to cause explain the disorder is not identified. A corollary of 
the need to screen for de novo inheritance is that, when possible, exome or genome 
sequencing of parents in addition to probands will substantially increase diagnostic yield 
in founder populations. 
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2.8 Chapter 2 Figures: 
 
 









Figure 6: Photographs of: A. the patient face at age of 1 year and 9 months. B. the 








Figure 7: A. DNA sequence electropherograms of the c.755A>T mutation identified in 
exon 9 of PIGN in the patient, her brother, her two sisters, and her parents. B. Alignment 
of different PIGN amino acid sequences with human PIGN. The conserved aspartic acid at 




Figure 8: A. Gated granulocyte cells stained with mouse anti CD45. B. Surface expression of overall GPI-anchored proteins as revealed 
by FLAER expression on blood granulocytes. C–E. Expression of CD24, CD18 and CD16, respectively, on blood granulocytes. The dark 









 Hirschsprung’s disease is characterized by the lack of ganglia in the myenteric 
and submucosal plexuses of the gut. It is a “model” complex disorder because it 
exemplifies multifactorial inheritance and yet has been molecularly tractable (Amiel et 
al., 2008; Carter, 1969; Chakravarti & Lyonnet, 2001). The disease (with an incidence of 
15 cases per 100,000 live births) is characterized by high heritability (>80%) and marked 
sex differences (male:female ratio, 4:1) (Chakravarti & Lyonnet, 2001). Patients have 
aganglionosis affecting bowel segments of variable length, as a result of incomplete 
rostral-to-caudal enteric neuronal colonization; on the basis of these segment lengths, 
the condition is classified as short, long, or total colonic aganglionosis (see the 
Supplementary Appendix, available with the full text of this article at NEJM.org). 
Approximately 18% of patients have multiple anomalies, some with specific syndromes; 
approximately 12% have major chromosomal variants (Amiel et al., 2008; Chakravarti & 
Lyonnet, 2001). Features of Hirschsprung’s disease include its high (3 to 17%) sibling 
recurrence risk (i.e., the risk of being born with the disease, given that one full sibling is 
affected) and the variation in risk according to sex, segment length, and familiality 
(Chakravarti & Lyonnet, 2001). 
 Hirschsprung’s disease has multiple causes, although no environmental causes 
are known (Bodian & Carter, 1963; Passarge, 1967). Complex segregation analyses have 
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refined this view by showing genetic heterogeneity according to the extent of 
aganglionosis. The long form is characterized by autosomal dominant inheritance and 
the short form by recessive or multifactorial inheritance, and the variants associated 
with both forms have incomplete penetrance (Badner et al., 1990). This finding led to 
the discovery of 17 genes with approximately 500 rare disease-associated coding 
variants, chiefly the genes encoding the receptor tyrosine kinase RET and the G-protein–
coupled receptor EDNRB (Table S1 in the Supplementary Appendix) (Amiel et al., 2008; 
Edery et al., 1994; Emison et al., 2005, 2010; Garcia-Barcelo et al., 2009; Jiang et al., 
2015; Kapoor et al., 2015; Puffenberger et al., 1994). Four noncoding variants, 
individually conferring moderate risks (odds ratio, 1.6 to 3.9) but together conferring 
risk that can vary by as much as a factor of 30 with increasing risk allele dosage (Kapoor 
et al., 2015), are genetic modifiers of Hirschsprung’s disease (Arnold et al., 2009; Emison 
et al., 2010). These data suggest widespread and variable genetic susceptibility to the 
disease from multiple genes, reflected in the differing presentations and recurrence 
risks among relatives. 
 We suspected that, in contrast to the genetic risk factors for other complex 
diseases, many genetic risk factors make individually large contributions to the risk of 
Hirschsprung’s disease. We undertook genotyping, exome-sequencing, and functional 
assays to study pathogenic alleles in a set of patients with Hirschsprung’s disease with 
representative phenotypes. Beyond studying known genes and identifying new ones, we 
investigated the variation in risk according to the type of pathogenic allele, the 
contribution of each type of allele to Hirschsprung’s disease in the general population, 
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and the distribution of these types of alleles across phenotypes. Our primary goal was to 
enable genetic stratification of patients in order to determine how genetic susceptibility 
manifests in clinical disease and its penetrance. Such genetic stratification could be used 
to determine whether postsurgical outcome — for example, continued bowel 
dysfunction and enterocolitis, which is reported in 30 to 50% of patients (Dasgupta & 
Langer, 2008; Menezes et al., 2006) — is related to genotype. 
3.2 Methods 
 
Participants and Genome-wide Analyses: 
 
 We conducted exome sequencing of samples from 190 patients of European 
ancestry and 47 of their affected relatives (7 parents, 12 children, 17 siblings, and 11 
second-degree relatives) with diverse phenotypes. The control sample used in exome 
sequencing consisted of publicly available, ancestry-matched exome data on 740 
samples from the 1000 Genomes Project and the National Institute of Mental Health 
Repository. For the analysis of common noncoding variant studies, we used a different 
set of 627 control samples that were genotyped in our laboratory: 404 from the 1000 
Genomes Project and an additional 223 “pseudo-controls” (generated from the 
chromosomes not transmitted to the affected child in 254 parent–child trios) (Kapoor et 
al., 2015). For the analysis of copy-number variants, we used a third control set of 
19,584 adults of European ancestry (DePristo et al., 2011). 




 For assessing the effect of common noncoding variants, we used four disease 
associated SNPs — rs2435357, rs7069590, and rs2506030 in RET and rs11766001 in the 
SEMA3 gene cluster (Chatterjee et al., 2016; Kapoor et al., 2015). We have previously 
shown that the RET noncoding variants are located within transcription enhancers 
bound by the transcription factors RARB, GATA2, and SOX10; these variants lead to 
reduced RET expression and an elevated risk of Hirschsprung’s disease (Chatterjee et al., 
2016). Although the causality of the rs11766001 polymorphism in the SEMA3 locus is 
unproven, considerable data support causality or a strong association with a causal 
variant in SEMA3C or SEMA3D, which have been shown to be necessary for gut 
innervation (Jiang et al., 2015; Kapoor et al., 2015). Coding pathogenic alleles at each 
gene were defined as nonsense or missense changes in codons encoding amino acids 
that are conserved (with respect to their position in the oligopeptide) across species, 
splice-site single nucleotide variants, and all coding insertion–deletion variants with a 
frequency of 5% or less. These definitions gave acceptable levels of true and false 
positives at known Hirschsprung’s disease genes (Table S1 in the Supplementary 
Appendix) (Stenson et al., 2014). Disease-associated coding variants can have 
incomplete penetrance and be present in controls; therefore, we identified 
Hirschsprung’s disease-associated genes as those that had a greater number of unique 
pathogenic alleles in patients than in controls (Fig. S4 in the Supplementary Appendix). 
We assessed large copy-number variants (deletions of more than 500 kb and 
duplications of more than 1 Mb) with a frequency of less than 1% among controls to 
determine whether they were significantly enriched among patients or had previously 
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been found to be associated with a developmental disorder (Tables S8 and S9 and Fig. 
S5 in the Supplementary Appendix) (DePristo et al., 2011; Itsara et al., 2009). Additional 
details are provided in the Methods section in the Supplementary Appendix. 
 To assess the role of a gene in Hirschsprung’s disease, we first used reverse 
transcriptase polymerase chain reaction (RT-PCR) to assess its RNA expression 
in the human embryonic gut at Carnegie stage 22, by which time gut neurogenesis is 
complete (Fig. S6 in the Supplementary Appendix). Second, we tested gene expression 
by RNA sequencing and RT-PCR in the developing mouse gut during the equivalent 
developmental period (embryonic day 10.5) (Fig. S6 in the Supplementary Appendix). 
Third, we used morpholinos (antisense oligonucleotides) to knock down gene 
expression in zebrafish embryos at 6 days after fertilization and enumerated the enteric 
neurons colonizing the gut relative to controls (Fig. S7 in the Supplementary Appendix) 
(Jiang et al., 2015). 
Statistical Analysis: 
 
 Population-level risks were estimated for groups of pathogenic alleles, genes, or 
loci with the use of odds ratios with significance thresholds (corrected for multiple 
testing) and 95% confidence intervals (Kapoor et al., 2015; Purcell et al., 2007). The odds 
ratios were converted to estimated population penetrance (equivalent to the 
population incidence or risk) with Bayes’ theorem, under the assumption of an 
incidence of 15 cases per 100,000 European-ancestry live births (Emison et al., 2010). 
Allele frequencies among controls were obtained from a variety of public resources (Coe 
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et al., 2014; DePristo et al., 2011; The 1000 Genomes Project Consortium, 2015) to 
estimate the population attributable risk. Additional details are provided in the Methods 
section in the Supplementary Appendix. 
3.3 Results 
 
Common Regulatory Variants and Risk: 
 
 Four common transcription-enhancer variants were associated with a moderate 
risk of Hirschsprung’s disease in our sample of 190 patients and 627 controls (Table S2 in 
the Supplementary Appendix) (Emison et al., 2005, 2010; Garcia-Barcelo et al., 2009; 
Jiang et al., 2015; Kapoor et al., 2015). The frequency of these variants allowed us to 
estimate their total effect according to dosage in reference to persons with one allele 
(none had zero alleles): a risk of Hirschsprung’s disease (odds ratio >1) is evident only 
with three or more alleles (Table 1), but, in view of multiple comparisons, the risk was 
considered significant only when at least five risk alleles were present (odds ratio, 4.54; 
95% confidence interval [CI], 3.19 to 6.46; P = 1.22×10−16) (Table 2). Thus, the population 
risk of Hirschsprung’s disease varies by a factor of 24, from approximately 1 case per 
19,100 live births (0 or 1 risk allele) to 1 case per 710 live births (seven or eight risk 
alleles) according to enhancer risk-allele dosage, which shows the wide differences in 
basal susceptibility to Hirschsprung’s disease. 
Risk Associated with Rare Coding Variants: 
 We first tested whether coding pathogenic alleles, as we defined them, for the 
17 known Hirschsprung’s disease genes statistically discriminated patients from controls 
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(Table S1 in the Supplementary Appendix). As compared with the 29 pathogenic alleles 
found in 71 (9.6%) of 740 controls, 36 pathogenic alleles were found in 41 (21.6%) of 
190 patients, a percentage 2.25 times as high (P = 5.97×10−6) (Table S6 in the 
Supplementary Appendix), which indicates a higher burden of pathogenic alleles in 
patients. Furthermore, the pathogenic alleles that were found in patients had a 
significantly lower mean frequency in an external reference population, the Exome 
Aggregation Consortium database (ExAC) (Exome Aggregation Consortium et al., 2016), 
than did the pathogenic alleles found in controls (5.58×10−4 vs. 1.11×10−3, P = 2.14×10−5) 
(Table S6 in the Supplementary Appendix), which indicates that the rare coding changes 
observed in patients have been subject to greater purifying selection than those 
observed in controls. That is, even though pathogenic alleles in both patients and 
controls met our definition of pathogenicity, when we compared the frequency of each 
set (variants in the patients being one set and variants in the controls the other) with 
the frequency of the specific variants of each set in persons in the ExAC database, those 
of the patient set were less frequent in the ExAC database than were those in the 
control set.  
To assess the enrichment of pathogenic alleles for each gene, we estimated the 
probability (P value) of finding as many or a greater number of distinct pathogenic 
alleles in patients, restricting our analysis to 15,963 single-nucleotide variants in 4027 
genes for which there was at least one identified pathogenic allele in both patients and 
controls. We identified 3 genes, EDNRB, ADAMTS17, and ACSS2 that exceeded the 
significance threshold of 1.24×10−5 (5% significance across 4027 genes) (Fig. S4 in the 
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Supplementary Appendix). More broadly, at a P value threshold of 0.001, we found 10 
genes instead of the expected 4 (P = 1.3×10−3) (Table 3). We performed functional tests 
on these 10 genes to distinguish false from true candidates. 
 The top 10 genes had a minimum of 4 pathogenic alleles each and included both 
of the major genes, RET and EDNRB. We also found evidence of 7 novel Hirschsprung’s 
disease genes — ACSS2, ADAMTS17, ENO3, FAM213A, SH3PXD2A, SLC27A4, and UBR4 
— on the basis of both an excess of pathogenic alleles and enteric nervous system gene 
expression in humans and mice during enterogenesis; assays in zebrafish further 
confirmed ACSS2, ENO3, SH3PXD2A, and UBR4 (Fig. S6 in the Supplementary Appendix). 
The 7 novel genes harbored 39 distinct pathogenic alleles occurring in 40 patients 
(21.1%), as compared with 23 distinct pathogenic alleles occurring in 28 controls (3.8%) 
(P = 3.46×10−16). Of the 39 pathogenic alleles in patients, only 6 were identified in 8 
controls (1.1%). When all 24 Hirschsprung’s disease genes were considered, we 
identified 75 unique pathogenic alleles occurring in 34.7% of patients (66 of 190), a 
percentage significantly higher than the 5.0% observed among controls (37 of 740; odds 
ratio, 10.02; 95% CI, 6.45 to 15.58; P = 3.41×10−25) (Table 2). The mean allele frequencies 
of the pathogenic alleles in patients and controls in the ExAC database are 4.22×10−4 
and 8.26×10−4, respectively, a difference similar in magnitude to the difference we 
observed for alleles in the 17 previously known Hirschsprung’s disease genes. The 
causality of these variants is further confirmed by higher-than-expected genotype 
concordance between probands with coding pathogenic alleles and their affected 
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relatives (P = 0.005) (Tables S6and S7 and the Methods section in the Supplementary 
Appendix).  
Pathways and Functional Groups: 
 
 Owing to genetic heterogeneity and chance fluctuations, the overall contribution 
of pathways to Hirschsprung’s disease can be estimated more accurately than that of 
individual genes (Table S7 in the Supplementary Appendix). In Hirschsprung’s disease, 
the RET and EDNRB signaling pathways play major roles with strong epistatic 
interactions (Edery et al., 1994; Emison et al., 2010; Puffenberger et al., 1994). Thus, we 
considered members of the RET (GDNF, NRTN, GFRA1, and RET) and EDNRB (ECE1, 
EDN3, and EDNRB) signaling modules for burden analysis. A third pathway, also epistatic 
to RET, involves the class 3 semaphorins and their receptors: here we consider only 
SEMA3C and SEMA3D because of their association with Hirschsprung’s disease (Jiang et 
al., 2015; Kapoor et al., 2015). A fourth class consists of the transcription-factor genes 
(SOX10, ZEB2, PHOX2B, and TCF4) that are critical to the early development of the 
enteric nervous system and harbor rare coding variants that cause Hirschsprung’s 
disease–associated syndromes (Table S1 in the Supplementary Appendix). We 
considered two additional categories: other known genes (KIF1BP, L1CAM, IKBKAP, and 
NRG1) (Amiel et al., 2008; Garcia-Barcelo et al., 2009) and the seven novel genes 
identified in this study. 
 We compared the total numbers of pathogenic-allele genotypes in each of these 
six classes or pathways among the 66 variant-positive patients with their corresponding 
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frequencies among controls (Table S7 in the Supplementary Appendix). Genes encoding 
members of the EDNRB pathway (odds ratio, 69.03; 95% CI, 8.68 to 547.92), 
transcription-factor genes (odds ratio, 4.15 to 307.72), and novel genes (odds ratio, 
23.2; 95% CI, 11.04 to 48.72) had the largest risk effects, followed by genes encoding 
members of the RET pathway (odds ratio, 16.03; 95% CI, 5.21 to 49.28) and SEMA3C and 
SEMA3D (odds ratio, 2.65; 95% CI, 1.25 to 5.60). Other known genes (odds ratio, 3.15; 
95% CI, 1.22 to 8.09) also made measurable risk contributions, but with an order of 
magnitude smaller effect. These risk rankings were reflected in the inverse contributions 
of these classes to the total risk of Hirschsprung’s disease. Pathogenic alleles causing 
greater risk probably have higher penetrance and are therefore selected against with 
greater intensity. If so, the abundant coding variants in genes of the RET pathway have 
lower penetrance than coding variants in the genes of the EDNRB pathway, the genes 
encoding transcription factors, and the novel genes. 
These data also indicate that RET has a smaller coding-variant risk burden than 
previously believed: 6.3% of the patients (12 patients) had RET coding pathogenic 
alleles, in contrast to approximately 50% from the older data (Chakravarti & Lyonnet, 
2001; Edery et al., 1994). This difference could arise from differing definitions of 
pathogenicity or from the preponderance of familial and severe cases in earlier studies. 
Nevertheless, RET regulatory pathogenic alleles, which have even lower penetrance 
than coding pathogenic alleles (Emison et al., 2005), were prevalent and, together with 
RET coding variants, conferred substantial risk in 92 of 190 patients (48.4%); this finding 
highlights the fact that reduced RET expression is the predominant cause of 
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Hirschsprung’s disease. Moreover, coding or noncoding (in the case of RET transcription 
enhancer variants) pathogenic alleles in affecting genes that encode members of the 
RET regulatory network (Chatterjee et al., 2016), which is made up of RET, its 
transcription factors (RARB, GATA2, and SOX10), its ligands (GDNF and NRTN), and its 
coreceptor (GFRA1), were found in 120 of our patients (63.2%). In contrast, genes of the 
EDNRB pathway contributed to only 8 cases (4.2%). 
Frequency of Copy-Number Variants in Hirschsprung’s Disease: 
 Of the 190 patients, 17 (8.9%) had syndromic presentations or known major 
chromosomal variants (Table 4). To detect subkaryotypic changes, we examined the 
exome data to identify large copy-number variants. In total, we identified 16 distinct 
copy-number variants; 14 of these variants (and their loci) were not previously known to 
be associated with Hirschsprung’s disease (Table 4). We assessed the pathogenicity of 
each variant on the basis of its enrichment in patients or their association with a known 
developmental disorder to identify 9 chromosomal variants and copy-number variants 
in 11.4% of patients (21 of 185), with a corresponding frequency of 0.2% (40 of 19,584) 
in controls, a highly significant effect (odds ratio, 63.07; 95% CI, 36.75 to 108.25; P = 
4.19×10−51) (Tables 2 and 4, and Table S9 in the Supplementary Appendix) (Amiel et al., 
2008; Badner et al., 1990; Chakravarti & Lyonnet, 2001). 
 Of the 21 instances of pathogenic chromosomal variants in patients, 18 (86%) 
were recurrent and 3 were nonrecurrent, and 18 were in patients with syndromic 
presentations (Table S9 in the Supplementary Appendix). The most frequent (11 
variants, 52%) recurrent finding was trisomy 21, but the other 7 occurred at well-known 
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loci for other genomic disorders. The elevated frequency of trisomy 21 among patients 
with Hirschsprung’s disease (odds ratio, 73.69; 95% CI, 34.97 to 155.29; P = 1.23×10−29) 
(Table 2) is not surprising, given previous observations (Arnold et al., 2009). However, 
the 16p11.2del copy-number variant, which is usually associated with autism (Betancur, 
2011), is also significantly enriched (odds ratio, 30.03; 95% CI, 9.70 to 92.97; P = 
3.62×10−9). Overall, the 9.7% frequency of patients with Hirschsprung’s disease who 
have recurrent chromosomal variants is significantly higher than the expected frequency 
(odds ratio, 53.30; 95% CI, 30.30 to 93.76; P = 2.60×10−43). These recurrent 
chromosomal changes are known to be associated with intellectual disability, autism, 
neurodevelopmental delay, epilepsy, and Charcot–Marie–Tooth disease type 1A 
(Betancur, 2011; Lupski et al., 1991), perhaps owing to pathways common to the enteric 
and central nervous systems. The three nonrecurrent variants, one of which deletes 
EDNRB, were unique, and all occurred in patients with syndromic presentations (Table 
4). 
Distribution of Diverse Pathogenic Alleles: 
 
Pathogenic alleles in at least 32 genes and loci contribute to Hirschsprung’s 
disease: rare coding variants in 24 genes, common noncoding variants at four sites 
within 2 loci, and large copy-number variants and chromosomal anomalies in at least 8 
additional loci (not including 13q21.33-q31.1del, which overlaps EDNRB). The common 
noncoding risk genotypes (five or more risk alleles), rare coding variants, and copy-
number variants occur at decreasing (by orders of magnitude) frequencies in the general 
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population — 17.1%, 5.0%, and 0.2% —but with increasing odds ratios of 4.54, 10.02, 
and 63.07, respectively (Table 2). In consequence, all three variant classes make major 
contributions to the risk of Hirschsprung’s disease, with population attributable risks of 
37.7%, 31.1%, and 11.3%, respectively, and a total attributable fraction of 61.9%. In 
addition, although the differences are not significant, the odds ratios among males are 
consistently higher than those among females (Table S10 in the Supplementary 
Appendix). Thus, the sex effect in Hirschsprung’s disease is not caused by a specific gene 
or variant but is a property of the disorder. We conclude that, first, even in this rare 
disorder, common variants are responsible for the majority of cases of Hirschsprung’s 
disease, despite their individually lower risks, because of their high population 
prevalence. Second, the total risk from all rare coding pathogenic alleles (which have a 
much higher penetrance) is also high but is differentially spread over 24 genes. Third, 
the population risk from copy-number variants is the lowest, spread over the effects of 
9 loci but with a majority contribution from trisomy 21. These risks from both known 
and novel genes and loci are almost certainly overestimates owing to the “winner’s 
curse.” Consequently, we reestimated the risks, taking into consideration only the well-
established risk factors and genes known before this study, and we found the same 
pattern: these variant classes occur at frequencies of 17.1%, 3.9%, and 0.1% in the 
general population, but with increasing risks — odds ratios of 4.54, 6.70, and 73.69, 
respectively (Table 2). These three categories contribute to the population attributable 
risks of 37.7%, 18.2%, and 9.1%, respectively, or a total attributable fraction of 53.7%. 
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Finally, we quantified the risk associated with combinations of pathogenic alleles 
(Table S11 in the Supplementary Appendix) (Angrist et al., 1996). We classified each 
patient’s total burden of pathogenic alleles according to sex, segment length, familiality, 
and the presence or absence of additional anomalies; we pooled all patients with copy-
number variants into one class, given the low frequency of this type of variant. The 
results showed three cardinal features (Table 5). First, genetic risk factors of any type 
were identifiable in 72.1% of patients, and patients harbored various combinations of 
different types of pathogenic alleles, all in significant excess relative to controls. Second, 
each of the three variant classes (five or more common noncoding variants, rare coding 
variants, and copy-number variants) were present in substantial percentages of 
diagnoses (48.4%, 34.7%, and 11.4%, respectively) (Table 2). One, two, or three different 
classes of molecular lesion were present in 51.9%, 18.4%, and 1.7% of patients, 
respectively — roughly their expected frequencies — with no evidence of interaction, a 
finding consistent with multifactorial expectations, although the statistical power for 
such detection is probably low (Table 5, and Table S11 in the Supplementary 
Appendix). Third, the genotype-specific odds ratios for Hirschsprung’s disease, 
estimated in reference to the class with no identifiable genetic risk factor, vary by a 
factor of 67 and increase with the pathogenic allele burden. These data allow us to 
estimate the absolute risk of Hirschsprung’s disease, given a person’s genotype. Persons 
with no identifiable risk factors have an estimated population risk of 5.33 per 100,000 
(approximately 1 per 18,800), a low risk of disease. At the other extreme, persons with 
both common enhancer risk genotypes and rare coding variants and those with copy-
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number variants have substantial estimated risks of 2.85 per 1000 (approximately 1 per 
350) and 8.38 per 1000 (approximately 1 per 120), respectively. 
We did not detect any significant genotype–phenotype associations with respect 
to sex, segment length, familiality, or syndromic status. However, patients with a copy-
number variant and patients with both a common transcription-enhancer risk genotype 
and a rare coding variant — the two classes with the highest relative risks — are 
characterized by an excess representation of males and of nonfamilial cases. The sex 
ratio in classes with no evident pathogenic alleles or those with rare coding single-
nucleotide variants only is approximately 1. This latter class is most often seen in 
persons with an affected relative (familial disease), which suggests that most 
segregating pathogenic alleles in affected families are rare coding variants. There was 
also a greater tendency for Hirschsprung’s disease to be syndromic among patients in 
higher risk classes than among those in lower risk classes. 
3.4 Discussion 
 
Hirschsprung’s disease can arise both from low-penetrance genetic disorders 
(Badner et al., 1990; Chakravarti & Lyonnet, 2001; Edery et al., 1994; Puffenberger et al., 
1994) and from high-penetrance monogenic syndromes (Amiel et al., 2008; Chakravarti 
& Lyonnet, 2001). Risk prediction and genetic counseling therefore depend on family 
history, risk factors (sex and segment length), and targeted assessment for syndromic 
features (Badner et al., 1990). Thus, in a small subset of patients, classical genetic 
testing of RET, EDNRB, and genes that are associated with syndromes may be 
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informative. The results reported here, however, suggest that widespread genomic 
analyses may be useful for clinical research and improved risk stratification. 
Hirschsprung’s disease is usually an isolated condition and unassociated with 
family history. However, genetic causal factors can be identified in approximately 72% 
of cases, for which molecular class, frequency, and disease risk can be quantified on the 
basis of sequence data alone, explaining between 53.7% and 61.9% of population 
attributable risk. Approximately 21% of patients have multiple risk factors, with the 
genotype-specific incidence increasing by a factor of more than 100 (risk ranging from 
approximately 1 in 18,800 to 1 in 120) as the number of genotypic risk factors increases 
from zero to three. Therefore, we have sufficient quantification of disease risk according 
to genotype to address questions of underlying causes and genetic architecture and to 
provide genetic counseling for the highest-risk 21% of patients and their relatives. 
We have made considerable strides in understanding the functional basis of 
Hirschsprung’s disease. The majority of the 32 genes and loci are known to have roles in 
the development of the enteric nervous system. In contrast, the majority of patients 
(63.2%) have identifiable pathogenic alleles only within the known RET regulatory 
network, which lead to decreased RET signaling. The RET effect is potentially even 
larger, affecting 78.9% of patients, because an additional 5.8% of patients harbor 
pathogenic alleles in UBR4, a novel E3 ligase gene identified in this study and a 
candidate for RET signal termination; 5.9% of patients have trisomy 21, which results in 
an elevated dosage of SOD1, encoding a negative regulator of RET (Arnold et al., 2009); 
and 4.2% of cases involve EDNRB, which is SOX10-regulated (Carrasquillo et al., 2002; 
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Stanchina et al., 2006). Thus, genetic testing of at least the RET regulatory network is 
warranted for risk stratification. 
In order to understand the biology of enteric nervous system cell proliferation, 
migration, colonization, and neuronal specialization, it is important to understand the 
steps subsequent to the transition and differentiation of enteric nervous system cells, 
such as the likely axonal guidance functions of SEMA3C and SEMA3D (Jiang et al., 2015). 
The seven novel genes identified here, all of which are expressed in the human gut at 
the appropriate developmental stages, probably control some aspects of axonal 
guidance, cell proliferation, and local inflammation (Table S12 in the Supplementary 
Appendix). We hypothesize that screening the genes regulating these processes in early 
gut development will further resolve the remaining approximately 40% of 
Hirschsprung’s disease risk. 
A continuing challenge in the study of Hirschsprung’s disease is to understand 
the cellular mechanisms underlying the disease. Whether we consider the persons with 
the highest (1 in 120) or lowest (1 in 18,800) risk, the absolute risk of disease is still 
small. What are the cellular events that trigger or prevent aganglionosis, given a 
particular genotype? A part of the answer is the existence of very rare de novo gene 
mutations affecting the enteric nervous system (Gui et al., 2017), which require larger 
cohorts of trios for the detection of an association. However, the incomplete 
penetrance of most Hirschsprung’s disease variants implies that stochastic, 
environmental, or epigenetic factors must be important. 
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In our study, we found that the risk of the complex phenotype that is 
Hirschsprung’s disease stemmed from a combination of variants in numerous genes and 
different classes of genetic variants: noncoding variants, single nucleotide variants and 
copy-number variants, and both rare and common variants. Despite the current thinking 
in human medical genetics, most of the risk of Hirschsprung’s disease arose from a 
common widespread genetic susceptibility, on top of which rare coding and rarer copy-
number variants exacerbated the risk. Despite this molecular diversity, the implicated 
genes clustered, on the basis of their known function, into gene regulatory networks 
(which, in Hirschsprung’s disease, regulate the transition from enteric neural crest cells 
to enteric neuroblasts, axonal guidance, and neuroblast proliferation), a model that may 




3.5 Support and Acknowledgements 
 
Supported by 
Supported by grants from the National Institutes of Health (MERIT award R37 HD28088 
to Dr. Chakravarti, R01 MH101221 to Dr. Eichler, and U54 HG003067 to Dr. Gabriel). Dr. 
Eichler is a Howard Hughes Medical Institute investigator. 
Financial disclosure 
Disclosure forms provided by the authors are available with the full text of this article at 
NEJM.org. 
Acknowledgments 
We thank the numerous patients and their family members, physicians, and genetic 
counselors who have contributed to these studies over the years; and Erick Kaufmann, 
Jennifer (Scott) Bubb, Sue Lewis, Maura Kenton, and Julie Albertus for family 




3.6 Chapter 3 Tables: 
 
Table 1. Population risk of Hirschsprung’s disease as a function of RET and SEMA3 non-
coding risk allele dosage. 
# risk alleles 
Number (%) of cases 
(n = 186) 
Number (%) of controls 
(n = 627) 
Odds ratio  
(95% CI) 
P 
1 9 (4.8) 87 (13.9) (1) - 
2 13 (7.0) 137 (21.9) 0.90 (0.38-2.13) 8.24×10-1 
3 40 (21.5) 172 (27.4) 2.16 (1.03-4.52) 4.28×10-2 
4 34 (18.3) 124 (19.8) 2.55 (1.20-5.42) 1.51×10-2 
5 35 (18.8) 84 (13.4) 3.87 (1.81-8.29) 3.01×10-4 
6 41 (22.0) 18 (2.9) 20.66 (8.84-48.31) 6.03×10-15 
7 & 8 14 (7.5) 5 (0.8) 24.28 (7.68-76.74) 1.72×10-8 
A total of 186 patients and 627 controls (404 samples from persons of European ancestry [excluding 
Finns] from the 1000 Genomes Project and 223 pseudo-controls (generated from the chromosomes not 
transmitted to the affected child from 254 parent–child trios with complete genotype data) were 
classified according to the number of Hirschsprung’s disease risk alleles present at RET single-nucleotide 
polymorphisms (SNPs) rs2435357, rs7069590, and rs2506030 and SEMA3 SNP rs11766001. All patients 
had at least one risk allele. Bold odds ratios indicated a significant association (calculated with a two-sided 
Fisher’s exact test) at a family-wise error rate of 0.05, after correction for performing six tests.  
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Table 2. Distribution of Hirschsprung’s disease risk by the molecular class of risk alleles. 
Disease-associated  




Odds ratio (95% CI)a 
% Population attributable 
riskb cases controls 
Enhancers, common variantsc known 2 48.4 17.1 
4.54 
(3.19 – 6.46) 
(P = 1.22 x 10-16) 
37.7 









(6.45 – 15.58) 
(P = 3.41 x 10-25) 
31.1 
known 17 21.6 3.9 
6.70 
(4.06 – 11.04) 
(P = 9.65 x 10-14) 
18.2 













(36.75 – 108.25) 






1 5.9 0.09 
73.69 
(34.97 – 155.29) 
(P = 1.23 x 10-29) 
9.1 
 aAlthough the differences were not significant, the odds ratios in males were consistently larger than those in females (Table S10 in the Supplementary 
Appendix). 
b The combined population attributable risk for all three classes of pathogenic alleles, under the assumption of independent effects, is 61.9% for all 24 known 
and novel loci and 53.7% for the 18 known loci. 
c Five or more common disease variants were observed in 90 of 186 patients and 107 of 627 controls. 
dRare coding sequence variants were identified in 66 of 190 patients and in 37 of 740 controls. 
eThe copy-number variants (CNV) that were considered to be pathogenic, as reported in this table and in all our other analyses of risk, were clinically identified 
alterations (e.g., trisomy 21 or 22q deletion) or deletions of more than 500 kb or duplication of more than 1000 kb, with a frequency of less than 1% among 
controls, that had previously been significantly associated with a developmental disorder. CNVs were identified in 21 of 185 patients and in 40 of 19,584 
controls. 





Table 3. Genes with an excess of rare coding pathogenic alleles in Hirschsprung’s disease. 
 
Genea 
# distinct PAs  
in 190 cases 
P 
Embryonic intestinal gene expression 







EDNRB* 6 0.22 1.35x10-7 Yes Yes Yes 
ADAMTS17* 5 0.23 4.45x10-6 Yes Yes NT 
ACSS2* 6 0.45 8.08x10-6 Yes Yes Yes 
RET 7 0.99 7.73x10-5 Yes Yes Yes 
SLC27A4 4 0.22 8.48x10-5 Yes Yes No 
SH3PXD2A 4 0.22 8.88x10-5 Yes Yes Yes 
MMAA 4 0.23 9.26x10-5 No No No 
ENO3 5 0.45 1.03x10-4 Yes Yes Yes 
FAM213A 4 0.40 7.51x10-4 Yes Yes No 
UBR4 11 3.47 9.52x10-4 Yes Yes Yes 
 aGenes that are statistically significant after multiple test correction for 4,027 genes are marked by an asterisk. 






Table 4. Karyotypes and large copy number variants (CNVs) in Hirschsprung’s disease. 









(n = 19,584) 
Recurrent Variants 
Free & mosaic trisomy 21* 47,710 Yes K (9 of 11) 11 17# 6.68 x 10-16 
16p11.2 del* 740 - 985 1 Yes/2 No K (1 of 3), E (3 of 3) 3 12 3.38 x 10-4 
1q21.1 dup 509 – 1,185  No E (3 of 3) 3 27 2.72 x 10-3 
1q21.1 del* 1,425  Yes E 1 6 6.37 x 10-2 
22q11.2 del* 8,000 Yes K 1 0 9.36 x 10-3 
Tetrasomy 22q* 1,447 Yes K 1 0 9.36 x 10-3 
17p11.2 dup (CMT1A) * 1,835 No E 1 5 5.49 x 10-2 
Non-Recurrent Variants 
47, XX, +der (15) t(4:15)* 
7,768 (chr4), 
3,800 (chr 15) 
Yes K, E 1 0 9.36 x 10-3 
1p33 del 582 No E 1 0 9.36 x 10
-3 
12p13.31 del 554 Yes E 1 0 9.36 x 10
-3 
13q21.33-q31.1 del* 14,356 Yes K 1 0 9.36 x 10-3 
2q21.2-q22.2 del* 8,847 Yes E 1 0 9.36 x 10-3 
8p23.3 del 579 Yes E 1 0 9.36 x 10-3 
2p25.3 dup 1,377 No E 1 1 1.86 x 10-2 
7q21.12 dup 1,498 No E 1 11 1.06 x 10-1 
10q24.3-q26.13 inv 25,600  Yes K 1 - - 
a Karyotype or CNV locus defined by genomic coordinates with prior evidence of pathogenicity marked by an asterisk; b Estimated smallest region from 
karyotype, exome sequence or SNP array data; c Detection by karyotyping (K) and exome sequencing (E), with validation by SNP array including two trisomy 21 
cases on whom we did not have a submitted karyotype; d Controls are from reference 21 but counts for 47, XX, +der(15) t(4:15) are for the two duplications at 
the translocation site, not the translocation, while control counts were not available and not expected for the 10q24.3-q26.13 inversion; e Bold P values are 


























Codingb CNVc Obs.d Exp.e 
- - - 
50 
(28) 
140.69 (1) 5.33 x10-5 26 (52) 17 (46) 28 (56) 38 (76) 







2.74 x10-4 35 (66) 24 (57) 36 (68) 46 (87) 







5.47 x10-4 14 (52) 9 (41) 14 (52) 17 (63) 








2.85 x10-3 24 (83) 14 (58) 24 (83) 20 (69) 







8.38 x10-3 29 (81) 18 (58) 30 (83) 21 (58) 
+ - + 
- + + 
+ + + 
a Common variant: 5 or more risk alleles at RET (rs2435357, rs2506030, rs7069590) and SEMA3D (rs11766001); b Coding: at least one rare, deleterious variant in 
any of the 24 HSCR susceptibility genes; c CNV (copy number variant): A clinically identified alteration (trisomy 21, 22q deletion, etc.) or rare deletion >500kb or 
duplication >1000kb that had previously been associated with a developmental disorder; d Numbers (%) of 179 cases with complete data for all three mutation 
classes; e Expected values are calculated from control frequencies in Table 2; f Odds ratios are calculated based on HSCR subjects (reference) having no 
detectable disease associated variants as defined in a-c; g Population incidences are calculated by assuming a total rate of 15 HSCR cases per 100,000 live births. 
Note that the observed numbers (50, 53, 27, 29 and 20) of the variant classes are close to expected numbers estimated from random association of disease 
variants (53.44, 50.12, 28.40, 26.64 and 20.41; 2 = 0.67, 1df, P = 0.41).
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3.7 Chapter 3 Supplementary Appendix 
 
3.7.1 Supplementary Methods 
 
Author contributions: 
J.M.T, T.M.T., S.C., A.K., C.B. and A.C. designed experiments. J.M.T, C.B. and A.C. wrote 
and edited the initial draft of the manuscript and contributed to genotypic risk 
estimation. C.B. and A.C. selected HSCR families for inclusion in this study.  J.M.T., A.Y.L., 
T.N.T., K.H.N. and C.B. contributed to calling and analysis of coding variation. N.K. 
performed exome-based CNV calling. A.Y.L. and T.N.T. contributed to CNV validation. 
M.X.S. performed zebrafish morpholino assays and analysis. S.C. performed gene 
expression assays and analysis. A.K. performed common risk polymorphism genotyping 
and analysis. B.C. performed control CNV genotyping. B.C. and E.E.E. contributed to 
functional classification and analysis of large CNVs. N.G. and S.G. performed genomics 
data generation. All authors had the opportunity to comment on and approve of the 
final manuscript. 
Sample ascertainment:   
 Affected individuals were selected from our collection of 636 families comprising 
their phenotypes, medical, pathologic and family history, and a blood/cell line/DNA 
sample. Affected persons were classified by segment length of aganglionosis into three 
groups: short-segment (S-HSCR: aganglionosis up to the upper splenic flexure), long-
segment (L-HSCR: aganglionosis beyond the splenic flexure) and total colonic 





family history) and occurrence of anomalies other than aganglionosis. We chose a 
sample of 304 HSCR cases for exome sequencing based on DNA availability and consent 
for genome studies. For sequence analyses, after data cleaning and quality control, we 
retained 190 independent, unrelated affecteds and their 47 affected relatives (data 
version 1.3); for this study, we did not use data on 35 individuals from a genetically 
isolated Old Order Mennonite population (Puffenberger et al., 1994), 5 samples with 
poor sequence quality, 24 admixed individuals and 3 individuals whose genetic 
relationships could not be verified against their pedigrees. The 190 independent 
unrelated individuals, whom we designate as ‘probands,’ were most often the actual 
proband but rarely an affected first degree relative with more complete data. The 
included individuals self-identified as being of European ancestry, which was checked 
for consistency with their genotype data (Figure S2). The case sample was composed of: 
(1) 122 (64%) males and 68 (36%) females; (2) 82 (43%) S-HSCR, 67 (35%) L-HSCR/TCA 
and 41 (22%) unknown (unspecified) segment length; (3) 125 (66%) simplex and 65 
(34%) multiplex families (24 sibs, 20 parent-child, 21 greater than first-degree); (4) 130 
(68%) non-syndromic, 6 (3%) single gene syndromes (3 Central Congenital 
Hypoventilation syndrome (CCHS) and 1 each of Waardenburg (WS), L1CAM (L1CAMS) 
and Bardet-Biedl (BBS) syndromes), 17 (9%) chromosomal variants (11 with Down 
syndrome and 1 each with 16p11.2 del, 22q11.2 del, tetrasomy 22q, 47, XX, +der(15) 
t(4:15), 13q21.33-q31.1 del, 10q24.3-q26.13 inv) and 37 (20%) with multiple anomalies 
not recognized as a specific syndrome. This sample selection had features comparable 





length cases, and comprised: 67%, 33% male/female; 39%, 29%, 32% S-/L-
&TCA/unspecified; 70%, 30% simplex/multiplex; and, 63%/37% non-syndromic/ 
syndromic. Finally, the sampled sibship size was 1, 2, 3 or 4 for 155, 23, 7 and 1 
individual, respectively. Subject ascertainment was conducted with written informed 
consent approved by the Institutional Review Board of Johns Hopkins University School 
of Medicine.  
 For European ancestry controls, we used publicly available exome sequence data 
from 370 NIMH controls (https://www.nimhgenetics.org/available_data/controls/) and 
370 EUR 1000 Genome (1000G henceforth) samples (85 Toscani in Italy, 97 Utah 
residents of Northern or Western European ancestry, 96 Iberians in Spain, and 92 British 
in England and Scotland, but excluding 101 Finns owing to possible founder effects) 
(www.1000genomes.org) (The 1000 Genomes Project Consortium, 2015), generated 
using the same reagents and procedures by the Broad Institute. For assessing admixture, 
we included all 2,302 1000G individuals with diverse ancestries.   
For common non-coding variant studies, we used a different set of controls 
genotyped in our laboratory because some of these genotypes were not publicly 
available: 404 EUR 1000G samples (excluding Finns) and an additional 223 pseudo-
controls, generated from the chromosomes not transmitted to the affected from 254 
HSCR parent-child trios (Kapoor et al., 2015). The differing numbers of EUR 1000G 
samples used depended on when the data were accessed and the numbers of samples 
available at that time.  





adult subjects of European ancestry (Coe et al., 2014). Different European ancestry 
controls were required to accommodate risk factors of different frequencies and the 
assays available in control samples. 
A summary of all cohorts studied and of the assays performed on them can be 
found in Supplementary Figure S9. 
Genotyping:  
 Genotype data for the polymorphisms rs2435357, rs2506030 and rs7069590 at 
RET and rs11766001 at SEMA3C/D were previously generated using Taqman assays in 
our laboratory, and have been previously reported (Chatterjee et al., 2016; Kapoor et 
al., 2015). In addition, HSCR cases with large copy number variants (CNVs; see below), 
together with their parents where available, were validated by genotyping using the 
Human Omni 2.5-4v1 BeadChip, using standard methods at the Broad Institute. 
Exome sequencing, variant calling and annotation:  
 Genomic DNA was used to capture exomes using the Agilent 44Mb Sure-Select 
Human All Exon v2.0 capture, and sequenced using the 76 base paired-end method on 
an Illumina HiSeq2000 sequencer with >80% of bases at a coverage of 30X. The 
sequence data were aligned by the Picard (http://picard.sourceforge.net) pipeline using 
hg19 with the BWA algorithm and processed with the Genome Analysis Toolkit (GATK) 
(DePristo et al., 2011) to recalibrate base-quality scores and perform local realignment 
around known insertions and deletions (INDELs) (H. Li & Durbin, 2009). BAM files were 
used to call single nucleotide variants (SNVs) and small (<50bp) insertions and deletions 





simultaneously across all HSCR cohort members and controls (amounting to 3,176 
samples) into a single VCF file. Initial filtering was done via the Variant Quality Score 
Recalibration (VQSR) method within GATK, which is based on detection of known 
variant sites. For SNVs, HapMap3.3 and Omni2.5 were used as training sites with 
HapMap3.3 used as the truth set. SNVs were filtered to obtain the highest confidence 
variant set achieving 99% truth sensitivity (1% false negative rate). For VQSR of INDELs, 
a set of curated INDELs obtained from the GATK resource bundle 
(Mills_and_1000G_gold_standard.indels.b37.vcf) were used as both a training and truth 
set. INDELs were filtered to obtain the highest confidence variant set achieving 91% 
truth sensitivity (9% false negative rate). Following initial filtering, an additional 
annotation was added for ancestral alleles using: 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/supporting/ancestral
_alignments/human_ancestor_GRCh37_e59.README.  
  SNVs and INDELs meeting initial filtering criteria were further filtered using 
several hard quality filters. First, all multi-allelic sites were removed. Second, they were 
filtered on strand balance and homopolymer criteria (FS > 50 and HRun > 5.0 for SNVs, 
FS > 200 and HRun > 10.0 for INDELs). Third, all individual genotypes with a depth < 10 
were removed. Lastly, the dataset was filtered by deleting variants with >10% missing 
genotypes, separately for autosomes and sex chromosomes, and separately for males 
and females. ANNOVAR was used for annotation of variants (Wang et al., 2010). 






 We assessed whether coding variant coverage and detection sensitivity were 
comparable between the 190 cases and 740 controls by summarizing sequencing 
coverage of coding genes targeted by our exome capture reagents (and the 24 HSCR 
genes specifically) and by counting singleton and doubleton variant sites per individual 
in each set, across all genes. As shown in Figure S8, these metrics are comparable; there 
are no significant differences across case and control exomes, except that the variance 
in coverage is smaller in cases. Thus, the sensitivity of variation detection is identical 
between cases and controls excluding the possibility of false associations through 
differences in sensitivity.  
 CNV analysis using exome sequence data: 
Mapping, CoNIFER and CNV Segmentation: Short reads from the exome 
sequencing experiment were split into 36bp chunks and mapped using the single-end 
mode of mrsFAST (up to two mismatches) to exons and 300bp flanking sequence 
extracted from the repeat-masked hg19 reference genome, using the target file for the 
Agilent SureSelect Target Enrichment capture platform. Next, we used CoNIFER and 
calculated RPKM values for 189,894 probes and exons derived from the target file. We 
set the --svd option to 12, and used default CoNIFER settings for all other options. 
Subsequently, the raw SVD-ZRPKM values were exported for downstream analysis. We 
used DNACopy and CGHCall to segment and assign probabilities to SVD-ZRPKM values. 
To prevent excessively strong SVD-ZRPKM signals from interfering with the models used 
by CGHCall to assign copy number, we clipped the signal at ±3 for each exon. 





Default options for CGHcall were used, and we allowed only “deletion” and 
“duplication” as called states. Using these parameters, we obtained 13,300 raw 
segments “deleted” or “duplicated”. These computational methods are not optimized to 
detect aneuploidies because the data are normalized by chromosome within each 
sample. 
Quality Control: We excluded samples with more than 200 calls after 
segmentation, as such sample have extremely high false discovery rates (FDR). Four 
samples (HSCR274, HSCR18, HSCR385 and HSCR178) with a total of 1,939 calls were 
excluded, leaving 11,361 calls. 
CNVR generation and call filtering: We clustered calls using a custom hierarchical 
clustering method which uses the pairwise reciprocal overlap (RO) between calls as a 
measure of distance. To prevent merging of large unique calls, the RO function was 
modified by a gamma tuning parameter, which weights the RO based on the total 
number of non-overlapping probes on each end. In this way, the function accounts for 
the uncertainty in breakpoints and RO for two small CNVs, while allowing two large 
overlapping CNVs to be counted as distinct entities. Calls were merged using 
hierarchical clustering (WPGMA, weighted pair group method with averaging), and we 
flattened the resulting trees to form CNVR clusters. Using this method, we generated 
3,129 CNVRs. 
Filtering segmentally duplicated regions and processed pseudogenes: We 
excluded CNVs which were found to have more than 50% of their probes within 





methods from 1000 Genomes whole-genome depth-of-coverage analysis, where >80% 
of 34 unrelated genomes had a copy number three or greater in 500bp repeat-masked 
windows across the genome). Excluding calls which overlapped at least 50% with these 
regions resulted in the exclusion of 5,079 calls (45% of all calls), corresponding to 525 
CNVRs. Next, we excluded calls which were likely to be due solely to the insertion of 
processed pseudogenes. CoNIFER, and most exome-based read-depth methods, are 
sensitive to copy number changes, specifically of exons, which can be the result of retro-
insertion of processed mRNA transcripts (Krumm et al., 2012). We used two lists of 
commonly polymorphic processed pseudogenes generated using SPLIT-READ from 225 
autism trios (data not reported here) (Karakoc et al., 2012). We excluded calls from our 
call list for which ≥90% of the probes corresponded to a gene which had been observed 
at least twice in 225 trios. This excluded a total of 1,063 of 10,927 calls. In sum, our 
processed pseudo-genes, segmental duplications and other duplicated portions of the 
genome accounted for 5,808 calls in 673 CNVRs. 
Final filtering and call set generation: Our final set of calls and CNVRs was 
created by requiring at least one call in a CNVR with the following attributes: 1) an 
absolute median SVD-ZRPKM score (i.e., signal strength) of ≥ 1.5, 2) a CGHCall posterior 
probability of 0.95 or greater, and 3) passing additional filters for duplicated genes and 
regions as described above. Our final high-quality set of CNVRs contains 1,597 calls in 
554 CNVRs. For the current study, we restricted attention to only 111 rare large CNVs, 
defined as deletions >500kb and duplications >1mb, and potentially with phenotypic 





by karyotype or FISH (fluorescent in situ hybridization) for clinical diagnosis, loci for 
known genomic disorders and HSCR genes. All these cases were further validated by 
SNP genotyping using the Human Omni 2.5-4v1 BeadChip array (see Genotyping). 
Validating CNV calls: Omni2.5 Beadchip genotype data were processed using a 
standard Illumina pipeline; 4 samples failed the QC process. We manually examined the 
data to confirm each CNV by plotting B allele frequency and the LogR Ratio (LRR) for 
each from the gtc file. For each chromosomal position, we ignored samples if either the 
B allele frequency or LogR Ratio was missing, if the GCScore ≤ 0.15, and if multiple 
discordant genotype calls were made. We also noted the following: annotated genes in 
the region, and exome sequencing coverage. We validated 31 cases, as shown in Table 3 
and Supplementary Table S8, 22 cases of 8 unique recurrent CNVs and 9 non-recurrent 
CNVs. Of the 14 CNVs not evident from karyotypes, 13 had the median SVD-ZRPKM 
cutoff >1.5, and 1 between 1 and 1.5. Of the 17 validated CNVs in 31 cases, we could 
determine parental origin in 8 cases: 4 were de novo (del13, +21, 1q21.1 del, inv 10), 2 
were inherited from the father (17p11.2 (CMT1A) dup, dup7), 1 was inherited from the 
mother (t4;15); 1 was not inherited from the father but maternal origin could not be 
assessed since her sample failed QC (+21). We also identified an additional 4 kb RET 
deletion (chr10:42917793-42922026) in patient HSCR472 which was separately 
validated by qPCR analysis; note that the chromosome 13q21.33-q31.1 deletion 
included EDNRB.  





Principal component analysis (PCA): To assess population structure and potential 
cases of admixture, we conducted standard PCA analysis using R package SNPRelate 
(Zheng et al., 2012) on all 301 HSCR cases and 2,672 controls (370 NIMH samples and 
2,302 1000G) to identify 29 highly-admixed HSCR individuals (potentially African- and 
Asian- Americans). We used genotypes for 7,536 autosomal SNPs from exome 
sequencing that had allele frequencies 10%, missingness <5%, LD trimmed using an r2 
threshold of 0.2. In Supplementary Figure S2 we show European ancestry HSCR 
probands and all 2,672 PCA controls plotted along the first three PCs, followed by the 
first three PC’s of a Europeans-only PCA, showing that the only European ancestry group 
from whom HSCR probands can be discriminated is Finns. 
Sequence similarity between relatives: The exome sequence data were used to 
assess the overall genetic relationship between each case and his/her relative. Our 
sample included 42 relatives of 190 probands yielding 53 relative pairs from 32 families. 





where, nx, ny and nxy refer to the number of distinct alleles at variant sites in individual x, 
in individual y, and shared by x and y, respectively, at a variant site and is summed 
across all variant sites (C. C. Li et al., 1993). S = 0 whenever nx, ny or nxy is zero. S is the 
proportion of shared sites relative to the harmonic mean of the number of variants in 
the pair compared. The coefficient of relationship (r) is then estimated as: 





where 𝑆̅ is the average S across all variants, estimated by summing the numerator and 
denominator in the above formula, and U is the similarity statistic from unrelated 
individuals, estimated from all possible pairings of the 190 cases (C. C. Li et al., 1993). 
 To assess whether susceptibility variants were enriched in affected relatives of 
probands, we estimated S for the 24 HSCR genes, based on pathogenic alleles. We 
estimated the mean S for all such relative pairs and compared it to its expectation by 
obtaining its empirical distribution from 5,000 means based on 24 randomly selected 
genes for each relative pair, restricting analysis to only those gene sets with at least one 
pathogenic allele in the proband. This distribution was used to calculate a one-sided test 
of excess sharing in these relatives. Across all relative pairs, 𝑆̅ = 0.75 and was 
significantly greater than the mean permuted value of 0.45 (P = 0.0054). 
Discovery of genes enriched for rare coding single nucleotide variants (SNV): We 
compared rare pathogenic SNVs, defined as coding alleles that are nonsense, highly 
conserved missense (PhyloP score ≥ 4) or changes that alter the canonical ±2bp splice 
junctions, with frequency  5% in cases and controls for genes in which at least one 
pathogenic SNV was observed in controls. For analysis, we used the observed number 
(d) of distinct pathogenic SNVs among the 190 cases (do), motivated by the known 
distribution of allele multiplicity for alleles of a defined selection coefficient (Hartl & 
Campbell, 1982). To assess whether the observed value was higher than expected we 
used 740 European ancestry NIMH and 1000G controls to randomly sample 190 
individuals and calculate d for each replicate. Repeating this sampling 10,000 times, with 





mean ?̅?. We estimated the significance value () of the hypothesis of no gene effect as 
 = Prob {d  do|?̅?} and by assuming d is Poisson distributed, an assumption that was 
tested from the empirical distribution of d across the replicates. This assumption was 
conservative since the observed variance of the distribution was smaller than the 
average (Supplementary Figure S4). Note that these are gene-specific estimates and so 
no corrections for gene size or sequence features are necessary, although the statistical 
power of detecting departures in individual genes decreases with a gene’s increasing 
intrinsic rate of pathogenic variation in controls. This empirical probability distribution, 
contrasted to the expected distribution, for all human genes was used for testing 
whether there is an excess of pathogenic variants in specific genes (see QQ plot in 
Supplementary Figure S4). 
Discovery of copy number variants (CNV): CNV burden was compared between 
cases and controls for rare CNVs (prevalence <1%) using CNV length, excluding gaps and 
regions annotated as segmental duplications (hg18). The 19,584 controls (Coe et al., 
2014) were obtained by combining 8,329 controls from Cooper et al. (dbVar study 
accession nsdt54) with 11,255 new controls profiled on Affymetrix SNP6 arrays from the 
Wellcome Trust Case Control Consortium 2 (WTCCC2) 58C cohort, as well as the ARIC 
(Atherosclerosis Risk in Communities) Cohort (database of Genotypes and Phenotypes, 
dbGaP accession phs000090.v1.p1) (Supplementary Table 1 in (Coe et al., 2014). The 
details of CNV calling in controls are described there. CNV calls that falsely extended 
across centromeric gaps, due to small polymorphisms on both arms, were trimmed. 





defined using only the largest CNV to account for the large number of bases 
encompassed by small CNVs and the difference in resolution between cases (exome 
sequence) and controls (SNP arrays).  The overall incidence of rare deletions and 
duplications among these 19,584 controls was 0.020 (391 instances) and 0.014 (282 
instances), respectively. These controls did not include individuals with intellectual 
disability and so this estimate was supplemented by the prevalence of Down syndrome 
in the population (8.27/10,000 individuals) (Presson et al., 2013), and its value imputed 
for controls of equivalent size (i.e., 19,584).  
Quantifying pathogenic allele (PA) enrichment: We tested for enrichment of PAs 
by class in individuals of European ancestry. (1) Common variants were allele, haplotype 
and genotype counted in 186 cases and 627 controls with tests conducted using 
contingency chi-square methods with significance calculated using a 2-sided Fisher’s 
exact probability. Frequency differences were represented as corrected odds ratios 
(Kapoor et al., 2015) with variances and tests of significance as estimated using the 
Haldane bias correction (Haldane, 1956). (2) Rare coding variants were compared using 
exome sequence data in 190 cases and 740 1000G and NIMH controls. For overall 
enrichment, the PA definition for rare coding variants was extended to include all 
INDELs overlapping the coding sequence and restricted to only PAs identified in cases. 
For these alleles, we report their allele frequencies in ancestry-matched, non-
neuropsychiatric samples from ExAC (Exome Aggregation Consortium et al., 2016), 
comprising a much larger sample size of 21,071 subjects. Frequency differences were 





al., 2015) with variances and tests of significance as estimated using the Haldane bias 
correction (Haldane, 1956). (3) Each recurrent and non-recurrent CNV was compared 
against its frequency in a sample of 19,584 adult subjects of European ancestry. Tests of 
enrichment used a 2-sided Fisher’s exact probability. Note that these controls were all 
ascertained as adults and therefore were depleted for high penetrance CNVs such as 
trisomy 21, which we corrected for individually. The other CNVs detected are not a 
priori known to lead to high penetrance phenotypes. 
Estimating disease penetrance: Phenotype penetrance refers to the probability 
of phenotypic expression for specific genotypes and, as such, are marginal effects 
averaging across the phenotypic effects (if any) across all other genes (genetic 
background). As such, this penetrance is also the disease incidence given that genotype. 
The incidence is the frequency (rate) of new cases which may manifest or be recognized 
at different ages. However, for HSCR these are nearly identical because most cases are 
recognized and treated in the first years of their life. Consequently, genotype-
dependent penetrance can be calculated as follows: 
𝑃{𝐷|𝐺} = 𝑃{𝐺|𝐷}𝑃{𝐷}/𝑃{𝐺}, 
where G, D and Dc are genotype, phenotype (disease) and the phenotype complement, 
respectively, and P {.} is probability. If we examined n cases and m controls, and P{G} 
was the population frequency of a specific genotype class (either at one locus or at 
many) then it could be estimated from the control data, while P{G|D} could be 





and for HSCR is set to 15/100,000 live births. The penetrance estimated from the above 








which is estimated by replacing all expected values by their observed quantities. 
Estimating population attributable risk: Population attributable risk (PAR) is the 
proportion of disease in a population involving a given exposure, which is useful in this 
study for comparing the relative contributions of each risk factor to the development of 
HSCR. In order to estimate PAR, one requires an estimate of the relative risk (RR) of each 
risk factor as well as the proportion of the general population exposed. When disease 
incidence is low, as is the case with HSCR, RR ~ OR. Therefore, PAR can be estimated for 
HSCR risk factors as follows: 
𝑃𝐴𝑅 =  
𝑃𝑒 (𝑂𝑅 − 1)
𝑃𝑒  (𝑂𝑅 − 1) + 1
 
where Pe is the proportion of the general population exposed to that risk factor derived 
from one of our three control populations. 
 
Gene expression studies: 
Taqman gene expression assays of human and mouse gut tissue: We studied 8 
human fetal guts at Carnegie Stage 22 (CS22) obtained from the Human Developmental 
Biology Resource (www.hdbr.org; grant 099175/Z/12/Z). All HDBR samples were 
collected according to local Research Ethics Committee review by the NHS Health 





guidelines laid out in the Polkinghorne Report (Review of the Guidance on the Research 
Use of Fetuses and Fetal Material, 1989).  The HDBR is also licensed as a tissue bank by 
the Human Tissue Authority. The samples were approved for use in this study by the 
Institutional Review Board of Johns Hopkins University School of Medicine. All mouse 
guts used were from three E10.5 wild type C57BL/6J male mice purchased from The 
Jackson Laboratory. Total RNA was extracted from these tissues using TRIzol (Life 
Technologies, USA) and cleaned on RNeasy columns (Qiagen, USA). 500ng of total RNA 
was converted to cDNA using SuperScriptIII reverse transcriptase (Life Technologies, 
USA) and Oligo-dT primers. The diluted (1/5) total cDNA was subjected to Taqman gene 
expression (Life Technologies, USA) using transcript-specific probes and primers.  
Human or mouse β-actin was used as an internal loading control to normalize data. 
Each sample was assayed 3 times and the data presented are means with their standard 
errors. The relative fold-change was calculated based on the 2Ct (threshold cycle) 
method, with the highest expressing transcript (lowest Ct value) set to unity. Any gene 
with Ct value >30 was considered not expressed. Only one potential gene- MMAA had a 
Ct value >30 in both mouse and human. The following Taqman probes were used from 
Applied Biosystems: For human: RET (Hs01120032_m1), EDNRB (Hs00240747_m1), 
ADAMTS17 (Hs00330236_m1), ACSS2 (Hs01120914_m1), SLC27A4 (Hs00192700_m1), 
SH3PXD2A (Hs01046313_m1), MMAA (Hs00604098_m1), ENO3 (Hs01093275_m1), 
FAM213A (Hs00800009_s1) and UBR4 (Hs00390223_m1). For mouse: Ret 
(Mm00436305_m1), Ednrb (Mm00432989_m1), Adamts17 (Mm01318914_m1), Acss2 





(Mm04209905_m1), Eno3 (Mm00468267_m1), Fam213a (Mm00510430_m1) and Ubr4 
(Mm01348737_m1). 
RNA-seq gene expression assays of mouse gut tissue: Total RNA was extracted 
from 3 male mouse guts at E10.5. cDNA was prepared by oligo dT beads to select mRNA 
from the total RNA sample followed by heat fragmentation and cDNA synthesis from the 
RNA template as part of the Illumina Tru Seq™ RNA Sample Preparation protocol. The 
resultant cDNA was used for library preparation (end repair, base ‘A’ addition, adapter 
ligation, and enrichment) using standard Illumina protocols. Libraries were sequenced 
on a HiSeq 2000 using manufacturer’s protocols to a depth of 15 million reads per 
samples (75 base pair, paired end). The primary data were analyzed using the Broad 
Institute’s Picard pipeline, which includes de-multiplexing, and data aggregation. The 
resultant BAM files were mapped to the mouse genome (assembly mm10/GRCm38) 
using TopHat with its setting for paired end, non-strand specific library. Successfully 
mapped reads were used to assemble transcripts and estimate their abundances using 
Cufflinks (Trapnell et al., 2012). The resulting data assigned Fragments Per Kilobase of 
Transcript per Million mapped reads (FPKM) values for each transcript and gene. To 
further assign which genes were “expressed” in the gut, we did qPCR analysis of 
multiple genes with FPKM ranging from 1-10. Since we did not always detect expression 
of genes with FPKM < 5, we set FPKM of 5 as the threshold for genes to be considered 
gut expressed. All data have been deposited in NCBI’s GEO and are accessible at 






Morpholino studies in zebrafish: 
Zebrafish Maintenance and embryo collection: Zebrafish (AB strain) were raised 
and maintained under standard conditions. All animal research was approved by the 
Institutional Animal Care and Use Committee at Johns Hopkins University. Embryos 
were collected and staged as described previously (Kimmel et al., 1995; Westerfield, 
1991). 
Morpholino microinjections: Translation blocking morpholinos (MO) were 
designed against each zebrafish ortholog to the human gene and ordered from Gene 
Tools, LLC along with a standard negative control morpholino; the sequences are 
provided in Table S13. All genes had a single zebrafish ortholog except EDNRB for which 
both zebrafish orthologs were tested. Injections were performed on 1-2-cell zebrafish 
embryos (n=50) independently on at least 2 different days. Survival of uninjected, 
negative control and transcript-specific morpholino-injected embryos were recorded to 
assess the effect of the transcript-specific morpholinos on survival. Different 
concentrations were injected for each MO to determine the optimal concentration at 
which a phenotype was detected. Only two concentrations are being reported for each 
MO for simplicity; the lowest concentration at which an effect, if any, is seen and the 
highest concentration before the morpholino is lethal to the embryo. 
Immunostaining and visualization: Injected zebrafish embryos were fixed at 6 dpf 
(days post-fertilization) with 4% paraformaldehyde (PFA). Monoclonal anti-HuC 
antibody (Invitrogen #A-21271.) followed by Alexa Fluor 568 F (ab’)2 fragment of goat 





labeling of enteric neurons as previously described, with a mild modification (see Jiang 
et al., 2015) (Kuhlman & Eisen, 2007). The embryos were bleached after fixing in 4% PFA 
by incubating in 3% H2O2/0.5% KOH medium until there was a complete loss of 
epidermal pigmentation (~30-45 min), followed by a 5 min wash with PBS to stop the 
bleaching reaction. Stained embryos were visualized using a Nikon SMZ 1500 
fluorescent microscope using a DS red filter to assess the colonization of enteric neurons 
in the gut of each embryo.  
Cell counting: Stained neurons were counted using the Image-based Tool for 
Counting Nuclei (ITCN) plugin in ImageJ visualization software (Abràmoff et al., 2004), 
with the following parameters: width 9 pixels, minimum distance 4.5 pixels, threshold of 
1 and using a selected Region of Interest (ROI).  Since the enteric neurons are mostly 
lost caudally in the gut in well-established HSCR models in zebrafish, we chose our 
region of interest as 8 somites starting at the caudal end of the gut and going rostral. 15 
embryos were used for cell counting for each concentration of morpholino for each 





3.7.2 Chapter 3 Supplementary Tables 
 
Supplementary Table S1: Genes with disease-associated variants (DAV) and pathogenic 
alleles (PA) reported in HSCR mutation databases. 
 
HGMD and ClinVar reported 489 DAVs for HSCR, but our criteria for identifying a PA 
would have identified a smaller set of 395 (80.8%) alleles. These databases do not 
specify why most alleles are considered pathogenic. Note that the average allele 
frequency of these PAs is ~15X smaller than the corresponding DAVs suggesting a 
greater deleterious effect (penetrance). However, these PAs are a biased set since 
66.6% of them are null alleles which are easier to recognize as pathogenic and are, 
therefore, preferentially reported in the literature: 96 (24.3%) missense, 95 (24.1%) 
nonsense, 27 (6.8%) splice junction, (42.5%) frame-shifting INDELs, and (2.3%) non-
frame-shifting INDELs. As expected, the null alleles are extremely rare and at ~400X 
lower frequency than all PAs, demonstrating an even greater deleterious effect or 
higher penetrance. Determining causality for missense variants is much more difficult 
and requires statistical analysis of enrichment using controls or functional studies or 
both. Note the wide variation in reported DAVs and PAs across the HSCR genes, 
including that of null alleles, indicating differential allelic effects across genes. 
Consequently, the reliance on null alleles only for gene discovery and reporting creates 
an extreme bias in HSCR, and other genetic studies, for gene identification. Unbiased 
studies of PAs in different genes require appropriate control data on those same alleles. 
The overall PA detection rate is not possible to estimate from these data since the total 
numbers of patients screened were not reported. In contrast, we can estimate the 
maximum ‘false’ positive rate of PA detection under our criteria at ~13.2% since 52 such 
PAs were identified in 98 of 740 NIMH and 1000G controls (Table S6), in whom 
knowledge regarding HSCR family history is absent. This is an upper estimate since true 






Gene Locus Syndrome # DAVsa # PAsb 





29 26 22 (84.6%) 
SOX101,5 22q13.1 Waardenburg, type 4 (WS4) 38 36 33 (91.7%) 
TCF41,5 18q21.2 Pitt Hopkins (PHS) 49 49 32 (65.3%) 
ZEB21,5 2q22.3 Mowat Wilson (MWS) 150 144 135 (93.8%) 
GDNF2 5p13.2 - 5 0 0 
NRTN2 19p13.3 - 2 0 0 
GFRA12 10q25.3 - 2 1 0  
RET2 10q11.21 - 132 77 29 (37.7%) 
ECE13 1p36.12 - 1 0 0 
EDN33,5 20q13.32 Waardenburg, type 4 (WS4) 15 6 4 (66.7%) 
EDNRB3,5 13q22.3 Waardenburg, type 4 (WS4) 42 36 12 (33.3%) 
SEMA3C4 7q21.11 - 2 2 0  
SEMA3D4 7q21.11 - 3 2 0 
KIF1BP5 
(KIAA1279) 
1oq22.1 Goldberg Shprintzen (GOSHS) 4 4 3 (75.0%) 
L1CAM5 Xq28 L1CAM (L1S) 10 8 1 (12.5%) 




- 3 2 1 (50.0% ) 











9.05 x 10-8 
 
1 Transcription factors: PHOX2B, SOX10, TCF4, ZEB2; 2 RET pathway: GDNF, NRTN, GFRA1, 
RET; 3 EDNRB pathway: ECE1, EDN3, EDNRB; 4 SEMA3 pathway: SEMA3C, SEMA3D; 
5Single gene syndromes: PHOX2B, SOX10, TCF4, ZEB2, EDN3, EDNRB, KIF1BP, L1CAM, 
IKBKAP; a DAV: disease-associated variant as reported in HGMD (Stenson et al., 2014) 
and ClinVar (Landrum et al., 2018); b PA: pathogenic alleles as defined in Supplementary 
Methods; c Null: nonsense alleles and frame-shifting INDELs. Note that alleles with 
multiple functional classifications were classified with the following order of priority: 
nonsense, splice junction, coding INDEL and conserved missense. The mean allele 
frequency was estimated from non-Finnish European ancestry subjects from the ExAC 
database; only individuals without a neuro-psychiatric disorder were included (Exome 






Supplementary Table S2: Four common non-coding variants in Hirschsprung disease. 
 
190 cases and 627 (404 Non-Finnish EUR 1000G + 223 HSCR pseudo-controls from 254 
trios) controls were genotyped for rs2435357, rs2506030 and rs11766001; rs7069590 
had genotypes for 186 HSCR samples. The disease associations of these variants have 
been previously published (Chatterjee et al., 2016; Jiang et al., 2015; Kapoor et al., 
2015); their properties in the sample studied here are shown below in Table S2.1. 
Unsurprisingly, the odds ratios have the same magnitudes as reported earlier in larger 
samples, providing confidence that the sampled cases studied here are representative 
of HSCR. The genotypes of 186 HSCR cases available for all four markers were next used 
to count the total number of risk alleles per individual, a summary measure of 
susceptibility arising from common variants in cases and controls, shown below in Table 
S2.2.  
 










RET rs2435357 (T/C) 0.59/0.23 4.8 (3.8-6.1) 6.0×10-40 
RET rs7069590 (T/C) 0.84/0.74 1.8 (1.3-2.5) 9.7×10-5 
RET rs2506030 (G/A) 0.54/0.40 1.7 (1.4-2.2) 2.2×10-6 
SEMA3 rs11766001 (C/A) 0.21/0.16 1.4 (1.1-1.9) 0.02 
 
Table S2.2: Common variant susceptibility distribution in HSCR. 
# risk 
alleles 
Number (%) of 
cases 
(n = 186) 
Number (%) of 
controls 
(n = 627) 
0  4 (2.2) 16 (2.6) 
1 5 (2.7) 71 (11.3) 
2 13 (7.0) 137 (21.9) 
3 40 (21.5) 172 (27.4) 
4 34 (18.3) 124 (19.8) 
5 35 (18.8) 84 (13.4) 
6 41 (22.0) 18 (2.9) 
7  12 (6.5) 5 (0.8) 





Supplementary Table S3: Exome sequence variation. 
 
The data used (v1.3) represents joint calling and analysis of 301 HSCR cases and 740 
controls all sequenced at the Broad Institute, Cambridge, MA. There were a total of 
306,910 SNVs, 3,646 insertions and 7,900 deletions for a total of 318,456 variants. 
Considering coding sequences only, there were 112,489 SNVs, 844 insertions and 2,753 
deletions for a total of 116,086 variants. The properties of these variants passing quality 
control (Supplementary Methods) among the 190 European ancestry cases by type, 
genomic location and frequency (common defined as a minor allele frequency (MAF)  




SNV INS/DEL Common SNV INS/DEL Common 
Autosomal 41,295   267/872 6,012 126,089 1,588/3,058 28,167 
X-linked 743  2/9 117 2,553 16/38 579 
Total 42,043 269/881 6,129 128,642 1,604/3,096 28,746 
 
In summary, we identified 49,322 coding variants in the 190 independent, European 
ancestry HSCR probands of which 8,506 were pathogenic (616 nonsense, 478 splice 
junction variants, 924 coding INDELS and 6,488 conserved (PhyloP  4) missense). 






Supplementary Table S4: Exome sequence data accuracy. 
 
For quality control (QC) of these data we compared the sequences of six duplicate HSCR 
samples and assessed their concordance to those of 33 duplicate pairs in the 1000G 
data. The case samples were compared at between 777,945 and 896,652 sites with 
discordance varying between 7.4 x 10-5 and 3.24 x 10-4 in contrast to a discordance of 
1.07 x 10-4  4 x 10-5 in controls. Therefore, the average discordancy rate is 1.57x 10-4. 
 
Sample  # sites # missing # concordant # discordant 
discordance 
rate 
HSCR2564 883,181 16,422 883,110 71 0.000080 
HSCR18 777,945 121,658 777,794 151 0.000194 
HSCR218 783,669 115,934 783,415 254 0.000324 
HSCR1572 896,652 2,951 896,565 87 0.000097 
HSCR430 892,302 7,301 892,236 66 0.000074 






Table S5: Sequence similarity between cases and their relatives. 
 
As a further check on data quality, we used the exome sequence data to assess the 
expected versus estimated genetic relationship between each affected and his/her 
sequenced relative. For these analyses, we used genotype data on 27,411 common 
autosomal exome variants for which allele frequencies were available from external 
controls (a subset of the data reported in Supplementary Figure S1). These estimates 
demonstrate the linear fit of observations to theoretical expectations (C. C. Li et al., 
1993). From these results we estimated the coefficient of relationship as shown below 
(see Supplementary Methods): 
 
Table S5.1: Similarity measures using common variants. 










0.5 (n = 41) 0.8910 0.9066 0.9079 0.9073 0.9092 0.9257 
0.25 (n = 7) 0.8587 0.8627 0.8667 0.8661 0.8683 0.8750 
0.125 (n = 4) 0.8338 0.8355 0.8367 0.8389 0.8400 0.8484 
0.0625 (n = 1) 0.8248 
0 (n = 17, 955) 0.8025 0.8125 0.8146 0.8145 0.8166 0.8270 
 
Table S5.2: Coefficient of relationship corresponding to similarity in Table S5.1. 
Expected coefficient 









0.5 (n = 41) 0.4123 0.4962 0.5032 0.5002 0.5103 0.5995 
0.25 (n = 7) 0.2381 0.2597 0.2810 0.2778 0.2899 0.3261 
0.125 (n = 4) 0.1036 0.1132 0.1193 0.1312 0.1374 0.1827 







Supplementary Table S6: Pathogenic allele distribution in cases versus controls. 
 
Exome sequence analyses of the 190 HSCR cases identified 10 genes showing 
enrichment in the number of distinct SNVs, including RET and EDNRB, which serve as 
positive controls (Table 2). Based on gene expression studies in the human and mouse 
embryonic gut, all genes except MMAA were considered to be HSCR-relevant. The 7 
novel genes identified had a total of 39 PAs (1 nonsense, 36 missense, 1 intronic and 1 
exonic splicing change) which occurred in 40 of the 190 (21.1%) subjects. However, 
these cases also had additional PAs in the 17 previously identified HSCR genes (Table 
S1). For completeness, we list below by gene (column 1), the numbers of PAs (column 2) 
and the numbers of affected individuals with these PAs (column 3) in all 24 HSCR genes 
among the 190 cases (Table S6). The allele frequencies of these PAs as estimated from 
non-Finnish European ancestry subjects without a neuro-psychiatric disorder from ExAC 
(Exome Aggregation Consortium et al., 2016) are shown in column 4 (Table S6). These 
data from HSCR patients are compared to two types of controls. In the first, we 
compared the numbers of PAs (column 5) and the numbers of individuals (column 7) 
with these alleles, defined identically as in HSCR cases, among 740 non-Finnish 
European ancestry 1000G and NIMH controls (Table S6). In the second, we counted the 
numbers of PAs and cases only for alleles observed in cases (columns 6 and 8). 
Estimating these numbers from ExAC is not possible because we do not have access to 
the genotypes of individuals.  
 Cases in this study harbored 36 distinct PAs in 17 previously known, 39 PAs in 7 
novel genes or a total of 75 distinct PAs in all 24 genes. These PAs occur in 41 (21.6%), 
40 (21.1%) and 66 (34.7%) individuals for the known, novel and all HSCR genes. The 
mean allele frequencies of these PAs in our sample of HSCR cases for known, novel and 
all HSCR genes are 5.58 x 10-4, 2.96 x 10-4 and 4.22 x 10-4, respectively, showing relatively 
little difference between these three categories, but being ~12 times larger than 
identically defined PAs reported for known genes in databases (i.e., 3.61 x 10-5) (Table 
S1). We suspect that this is owing to the selective reporting of more severe and rarer 
alleles in public databases and missing true disease variants of lower penetrance which 
are expected to have higher allele frequencies. 
 (i) We first tested whether our definition of PAs enriches for causal alleles among 
HSCR cases in the identified genes as compared to the 740 1000G and NIMH controls.  In 
controls, we identified 29 distinct PAs in the 17 previously known genes, 23 PAs in 7 
novel genes and 52 PAs in all 24 genes, and these occurred in 71 (9.6%), 28 (3.8%) and 
98 (13.2%) controls, respectively. Overall, identically defined PAs were identified in 
34.7% (66/190) of cases in contrast to 13.2% (98/740) of controls, demonstrating a 2.63-
fold enrichment (2-sided: P = 4.08 x 10-12).  This enrichment was evident for both known 
genes (41/190 in cases versus 71/740 in controls: 2.25-fold, P = 5.97 x 10-6) and, 
necessarily (identified using this criterion), novel genes (40/190 in cases versus 28/740 
in controls: 5.56-fold, P = 3.46 x 10-16). Observe also that in controls, these PAs had 
average ExAC allele frequencies of 1.11 x 10-3, 4.74 x 10-4, 8.26 x 10-4, in known, novel 





frequencies in HSCR patients (2-sided: P = 2.14 x 10-5, 0.066 and 1.62 x 10-5, respectively, 
for known, novel and all HSCR genes). Thus, our definition of PAs leads to enrichment of 
causal variants because these selected variants exist in significantly greater numbers in 
cases than in controls and they are significantly rarer in the population than similarly 
defined variant alleles in controls. Note that 98 of 740 controls or 13.2% of controls 
have PAs: these represent both non-causal alleles and low penetrance disease alleles 
unobserved in our cases. Thus, we have a maximum false positive rate of 13.2% in 
identification of causal alleles in cases. The true proportion of falsely identified PAs in 
cases is, however, much lower because causal alleles are enriched in cases. In any case, 
we have significant statistical evidence of an enrichment of HSCR causal alleles across all 
24 genes. 
 (ii) Given the effects of the 24 genes in HSCR, we assessed the impact of 
observed variants at these genes by performing direct association tests of variant 
frequencies in cases and controls by gene, i.e., we restricted attention to only PAs 
observed in cases. We observed 12 case-specific PAs (6 each for known and novel HSCR 
genes) among 37 (5.0%) of 740 controls (29 and 8 individuals for known and novel HSCR 
genes). Across all 24 genes, this number is significantly smaller than the 75 among HSCR 
cases (P = 9.15 x 10-55) and they occur in 37 controls which is also considerably smaller 
than that in the 66 HSCR cases (P = 2.27 x 10-31). The number of PAs identified in HSCR 
cases is 24-fold higher than in controls, and the number of individuals with such alleles 
is 7-fold greater than in controls.  These significant differences are true for both known 
and novel genes as a group. We do not have statistical power to assess these effects for 
individual genes but the results can be accumulated by pathways (see Table S1), as in 
the following Table S7, so that the relative contributions of different gene classes to 

























SOX10 1 1 0 0a  0b 0a 0b - 
PHOX2B 1 1 0 0 0 0 0 - 
ZEB2 2 2 0 2 0 2 0 3.57 x 10-5 
TCF4 0 0 - 0 0 0 0 - 
GDNF 0 0 - 0  0 0 0 - 
NRTN 0 0 - 0 0 0 0 - 
GFRA1 1 1 7.16 x 10-5 1 1 1 0 2.35 x 10-5 
RET 9 12 3.33 x 10-4 3 0 5 3 1.18 x 10-3 
ECE1 0 0 - 2 0 2 0 9.79 x 10-5 
EDN3 1 1 0 1 0 4 0 2.10 x 10-3 
EDNRB 7 7 0 1 0 1 0 2.37 x 10-5 
KIF1BP 1 1 7.18 x 10-5 3 0 5 0 1.40 x 10-4 
L1CAM 1 1 0 0 0 0 0 - 
IKBKAP 1 1 1.00 x 10-3 5 1 6 1 2.69 x 10-4 
SEMA3C 3 3 2.10 x 10-3 3 1 25 10 4.28 x 10-3 
SEMA3D 6 8 9.25 x 10-4 4 2 9 7 1.83 x 10-3 
NRG1 2 3 2.05 x 10-3 4 1 11 8 1.04 x 10-3 
ADAMTS17 5 5 2.95 x 10-5 1 0 1 0 4.00 x 10-4 
ACSS2 6 6 2.37 x 10-4 2 1 2 1 6.00 x 10-4 
SLC27A4 4 4 1.55 x 10-4 1 0 1 0 2.00 x 10-4 
SH3PXD2A 4 4 4.62 x 10-4 2 1 4 1 2.50 x 10-4 
ENO3 5 5 1.50 x 10-4 2 0 2 0 3.60 x 10-5 
FAM213A 4 6 7.30 x 10-4 1 1 2 2 2.80 x 10-3 
UBR4 11 15 3.50 x 10-4 14 3 17 4 4.10 x 10-4 
All Genes 75 66 4.22 x 10-4 52 12 98 37 8.26 x 10-4 




Table S7: Distribution and effect of case-observed PAs by pathway. 
These are data in Table S6 rearranged by gene class (defined in Table S1) with statistically significant odds ratios in bold. 
Pathway Genes # cases (n = 190) # controls (n = 740) 
Pathway odds 








NRTN 0 0 
GFRA1 1 0 








EDN3 1 0 















ZEB2 2 0 
PHOX2B 1 0 








L1CAM 2 0 
IKBKAP 1 1 
NRG1 3 8 
17 known genes all the above 41 29 
6.70 








ACSS2 6 1 
SLC27A4 4 0 
SH3PXD2A 4 1 
ENO3 5 0 
FAM213A 6 2 
UBR4 15 4 
All 24 genes all the above 66 37 
10.02 
(6.45 – 15.58) 
1 Odds ratios were calculated using the Haldane bias correction and by comparing 190 cases with 740 controls based on coding PAs observed in cases only.
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Table S8: Identifying CNVs using exome sequence, SNP array and karyotype data. 
 
Details of each CNV detected and validated, based on multiple data types, are shown 
with CNV location, type, size, chromosomal locus and observed numbers in 185 cases 
and 19,584 controls. We separately validated a 4 kb RET deletion (chr10:42917793-
























many dup 21 47,710 1-46,709,983 47 XX & XY, +21 + 11 174 6.68 x 10-16* 
HSCR2970 del 16 985 28299106-29283882 16p11.2 del + 
3 12 
3.38 x 10-4* 
 
HSCR4220 del 16 906 29372452-30278662 - + 
HSCR71 del 16 740 29372452-30112616 - + 
HSCR4522 dup 1 509 144126136-144634799 - + 
3 27 2.72 x 10-3 HSCR4584 dup 1 1,185 143565872-144750520 - + 
HSCR46 dup 1 971 143663355-144634799 - + 
HSCR3886 del 1 1,425 144751127-145931774 - + 1 6 6.37 x 10-2* 
HSCR491 del 22 8,000 16280000-24230000 22q11.2 del + 1 0 9.36 x 10-3* 
HSCR3186 dup 22 1,447 15826987-17273998 Tetrasomy 22q + 1 0 9.36 x 10-3* 
HSCR522 dup 17 1,835 13340236-15175628 - + 1 5 5.49 x 10-2* 
HSCR11 dup 4 7,768 183482167-191247414 47, XX, +der(15)t(4:15) 
+ 1 05 9.36 x 10-3* 
HSCR11 dup 15 3,800 61487053-65287054 
HSCR73 del 1 582 46916717-47498799 - + 1 0 9.36 x 10-3 
HSCR208 del 12 554 8102597-8656675 - + 1 0 9.36 x 10-3 
HSCR4368 del 13 14,356 70912755-85268645 13q21.33-q31.1 del + 1 0 9.36 x 10-3* 
HSCR3305 del 2 8,847 133437762-142284441 - + 1 0 9.36 x 10-3* 
HSCR423 del 8 579 1501255-2080313 - + 1 0 9.36 x 10-3 
HSCR241 dup 2 1,377 31566-1397283 - + 1 1 1.86 x 10-2 
HSCR500 dup 7 1,498 88227224-89725429 - + 1 11 1.06 x 10-1 
HSCR4178 inv 10 25,600 101900000-127500000 10q24.3-q26.13inv - 1 05 - 
1hg18 genome coordinates; 2 Human Omni 2.5-4 v1 BeadChip data; 3observed numbers (50% reciprocal overlap of each CNV) in 19,584 controls from (Coe et 
al., 2014); 4 controls used were ascertained as adults and not expected to include trisomy 21, the rate of which in 19,584 births was estimated from population 
studies (Presson et al., 2013). 5Note that the array studies in controls could not detect aneuploidies, translocations and inversions. The control counts for 47, 
XX, +der(15) t(4:15) are for the two duplications at the translocation site; for the 10q24.3-q26.13 inversion, control counts were not available and not 





Table S9: Inferring the phenotypic consequences of karyotype variants and CNVs. 
 
1 CNVs of interest were defined as deletions >500kb and duplications >1 mb with a control frequency of <1% (Kaminsky et al., 2011).  Considering all of these 
CNVs of interest (listed in Table S8) except for the 10q24.3-q26.13 inversion (because a control frequency could not be determined), we observed a total of 29 
cases (of 185) having a CNV of interest compared to an expected control frequency of 700 (of 19,584) corresponding to an odds ratio of 5.10 (95% CI: 3.43 – 
7.57, P = 4.27 x 10-11). However, most of these changes in controls do not have a phenotypic effect and were assessed against primarily known causal changes, 
which is why we decided to use only a smaller set of known pathogenic variants for risk estimation. 2Entries in bold are statistically significant after multiple 
(15) test corrections with overall significance level of 5%. 3 The presence of a CNV in a HSCR patient can be a causal event or an incidental finding. We assessed 
known CNV-HSCR associations, statistical evidence of a new CNV association (column 3) and previous CNV association with a developmental phenotype from a 
set of 29,085 cases of developmental disorders (DD) (Coe et al., 2014; Kaminsky et al., 2011), for assessing CNV pathogenicity. 4 VOUS is variant of unknown 
significance. We ultimately classified variants as “pathogenic” based on a known association with a developmental disorder; these pathogenic CNVs include 
Free and mosaic trisomy 21, 16p11.2 del, 1q21.1 del, 22q11.2 del, tetrasomy 22q, 17p11.2 dup, 47, XX, +der(15) t(4:15), 13q21.33-q31.1 del and 2q21.2-q22.2 
del.  
Karyotype/ copy number variant1 Syndrome P2 Assessment of Causality3,4 
Free & mosaic trisomy 21 Y 6.68 x 10-16 Pathogenic – known association (HSCR) 
16p11.2 del Y/2N 3.38 x 10-4 Pathogenic – known association (DD) 
1q21.1 dup N 2.72 x 10-3 Likely benign 
1q21.1 del Y 6.37 x 10-2 Pathogenic – known association (DD) 
22q11.2 del Y 9.36 x 10-3 Pathogenic – known association (DD) 
Tetrasomy 22q Y 9.36 x 10-3 Pathogenic – known association (cat eye) 
17p11.2 dup  N 5.49 x 10-2 Pathogenic - known association (CMT1A) 
47, XX, +der(15) t(4:15) Y 9.36 x 10-3 Pathogenic – large duplication with 4q partial trisomy 
1p33 del N 9.36 x 10-3 VOUS 
12p13.31 del Y 9.36 x 10-3 VOUS (large segmental duplication content) 
13q21.33-q31.1 del Y 9.36 x 10-3 Pathogenic – known association (DD) 
2q21.2-q22.2 del Y 9.36 x 10-3 Pathogenic – known association (DD) 
8p23.3 del Y 9.36 x 10-3 VOUS (genes in interval have deletions in controls) 
2p25.3 dup N 1.86 x 10-2 Likely benign 
7q21.12 dup N 1.06 x 10-1 Benign 
10q24.3-q26.13 inv Y - VOUS 
100 
 
Table S10: Comparison of genetic burden of classes of variation by sex. 
 
Disease-associated  
risk allele class 



























































1 Five or more common disease variants (Table 1) were observed in 90 of 186 cases and 
107 of 627 controls; 2 rare coding sequence variants (Table 2) were identified in 66 of 
190 cases with an expected rate of 37 in 740 controls; 3 copy number variants (Table 3) 
were identified in 21 of 185 cases with an expected rate of 40 in 19,584 controls. 4 The 
data relevant to 24 known and novel loci, and the 18 known loci, respectively, are 














# (%) Male / 
Female 
# (%) Short / 
Long & TCAe 
# (%) Simplex / 
Multiplex 
# (%) non-
syndromic / MAf 
- - - 50 (28) 26 (52) / 24 (48) 17 (46) / 20 (54) 28 (56) / 22 (44) 38 (76) / 12 (24) 
+ - - 53 (30) 35 (66) / 18 (34) 24 (57) / 18 (43) 36 (68) / 17 (32) 46 (87) / 7 (13) 
- + - 27 (15) 14 (52) / 13 (48) 9 (41) / 13 (59) 14 (52) / 13 (48) 17 (63) / 10 (37) 
- - + 13 (7) 11 (85) / 2 (15) 9 (82) / 2 (18) 12 (92) / 1 (8) 2 (15) / 11 (85) 
+ + - 29 (16) 24 (83) / 5 (17) 14 (58) / 10 (42) 24 (83) / 5 (17) 20 (69) / 9 (31) 
+ - + 1 (1) 1 (100) / 0 (0) 0 (0) / 1 (100) 1 (100) / 0 (0) 1 (100) / 0 (0) 
- + + 3 (2) 3 (100) / 0 (0) 2 (67) / 1 (33) 2 (67) / 1 (33) 0 (0) / 3 (100) 




115 (64) / 64 (36) 77 (54) / 66 (46) 120 (67) / 59 (33) 
124 (69) / 55 
(31) 
a Common variant: 5 or more risk alleles at RET (rs2435357, rs2506030, rs7069590) and SEMA3D (rs11766001); b Rare Variant: 1 or 
more rare, deleterious variants in any of 17 known and 7 new susceptibility genes identified in this study; c CNV (copy number 
variant): a clinically identified alteration (trisomy 21, 22q deletion, etc.), recurrent CNV or unique rare deletion >500kb or duplication 
>1000kb identified as pathogenic in Table S9; d 179 affected individuals with complete data for all three mutation classes; e Cases 
where segment length was uncertain have been excluded here; f Non-syndromic cases have no clinical diagnosis of recognized 















A plasma membrane protein whose knockdown induces breast cancer cell apoptosis; acts as a versicanase in 
development and is dysregulated by epigenetic alterations (Jiang et al., 2015; Kelwick et al., 2015). 
SH3PXD2A 
A lipid-binding cytoskeletal protein resident in the embryonic mesenchyme, binds many ADAM proteins and 
functions to locally degrade extracellular matrix during axon guidance through tissues. Analysis of zebrafish 
embryos and neural crest cells in vitro have indicated that Src-activated Tks5 (protein encoded by SH3PXD2A) 
is necessary for proper neural crest cell migration (Murphy et al., 2011). 
Cell growth & 
proliferation 
ACSS2 
Acetyl-Coenzyme A synthetase 2 is both cytoplasmic and nuclear. Despite having many functions in lipid 
synthesis and energy generation, it can affect transcriptional control and gene expression through p300-
catalyzed control of histone acetylation versus crotonylation (Sabari et al., 2015). 
SLC27A4 
A fatty acid transport protein localized to the endoplasmic reticulum and the plasma membrane which has 
acyl-CoA ligase activity and, therefore, could have functions that interact with ACSS2, since increased fatty 
acid synthesis is required to meet the demand for membrane expansion of rapidly growing cells. 
 UBR4 
A ubiquitin E3 protein ligase (component N-Recognin 4) localized to the cytoskeleton and the nucleus. 
Despite having a function required for the termination of RET signaling (performed by CBL (Mulligan, 2014)), 
UBR4 may also be involved in regulating acetylation versus ubiquitylation by competing for the same lysine 
residues in the regulation of fatty acid synthesis and cell growth (Lin et al., 2013). 




A cytoplasmic and mitochondrial redox-regulatory protein. Recently, sulfhydryl-mediated redox signaling in 
inflammation has been shown to have a significant role in neuro-degenerative diseases using RET target 




Table S13: Translation blocking morpholinos for zebrafish orthologs of HSCR associated 
genes 
Gene Transcript id Morpholino sequence 
Control - CCTCTTACCTCAGTTACAATTTATA 
Ret NM_181662 ACACGATTCCCCGCGTACTTCCCAT 
ednrba NM_131197 GGAAACGCATGACTATTTAACAGTC 
ednrbb XM_683473.5 GCAGCAGAATGACCGATGATGCCAT 
ubr4 XM_005162190 CTCCATCTCCTCCACTCGACGCCAT 
eno3 NM_214723 GCGTGAATCTTACTAATGGACATCC 
mmaa NM_001105112 AAAACTCTAGATGGACGCATCTTTC 
sh3pxd2aa NM_001160022 TTGGGAACTTGTCGAGTATCTGCAT 
slc27a4 NM_001017737 TGGCACACGCCAACCGCAACATCCT 
acss2 NM_001002641 CAATCAGAGAGTGCCAACACATATC 






3.7.3 Supplementary Figures 
 
Supplementary Figure S1: Allele frequency distribution of 28,746 common autosomal 






Supplementary Figure S2: Principal component analysis (PCA) of HSCR samples. 
 
In A and B, the first three PCs are plotted for PCA of 190 HSCR non-Mennonite 
independent cases (HSCR NI); 370 European American samples from NIMH (NIMH); 458 
East Asian samples from 1000G (ASN); 471 European samples from 1000G (EUR); 609 
African samples from 1000G (AFR); 308 American samples from 1000G (AMR); 456 
South Asian samples from 1000G (SAN). The results show clear overlap for all 190 HSCR 
cases with reference individuals of European ancestry. PCA of Europeans only (first 
three PCs plotted in C and D) showed that the HSCR cases cannot be distinguished from 















Supplementary Figure S3: Sequence similarity between relatives. 
 
The distribution of similarity scores (S) for the expected (pedigree-based) degree of 
relationship is summarized below (see data in Tables S5). S is linearly related to the 













































Supplementary Figure S4: Assessment of genes significantly enriched for PAs. 
 
We used computer simulations, using the control exome sequence data, to compare the 
observed to expected distribution of distinct pathogenic alleles (PA) for each of 4,027 
genes with at least one such variant in cases and controls. These were compared to their 
observed numbers in cases and are compared in the QQ plot below with a 95% 
confidence interval at each point. As explained in the main text, the top 10 genes were 
enriched as a group (P<0.001). Genes marked in green were previously identified HSCR 
genes and those marked in red are novel genes identified in this study. 
 
The statistical test for comparing observed to expected numbers of distinct PAs 
assumed a Poisson distribution of the number of distinct PAs in a sample.  This is a 
conservative assumption because comparisons of the variance to the mean of the 
number of distinct PAs in 190 samples, as assessed from replicate sampling from 
controls, shows considerably less-dispersion (see Supplementary Figure S10). The same 
statistical method was used to identify candidate HSCR genes from small INDELs. The 
test was applied to rare (MAF  0.05 in 190 cases or 740 controls) and common 
(MAF>0.05 in cases or controls) alleles for small insertions and deletions separately. 
There were 551 genes with rare small INDELs in both cases and controls but only one 
gene, FAN1, had a P value below 0.01. None of the 132 genes with common small 
INDELs showed any statistical significance. This is unsurprising given that most genes 








Supplementary Figure S5: CNV burden in HSCR. 
 
The proportion of samples with any CNV, in either HSCR or controls, is plotted against 
the minimum unique size of the largest CNV. The data shows that the distribution of 
CNVs in HSCR is significantly greater (P<2.2x10-16) than in controls by both the log-rank 
test and the Peto and Peto modification of the Gehan-Wilcoxon tests 
(https://stat.ethz.ch/R-manual/R-devel/library/survival/html/survdiff.html) (Harrington 
& Fleming, 1982). The lines cross at 500 kb. Note that CNV size in this analysis is 







Supplementary Figure S6: Gene expression of candidate HSCR genes in the embryonic 
human and mouse gut. 
 
Taqman gene expression profiles in human fetal gut tissue at Carnegie stage 22 shows 
all genes except MMAA are expressed at the relevant time point in development (A), 
with similar data from mouse gut tissues at E10.5 (B). The transcript with the highest 
expression was set to unity to compare the relative expression of other genes. The error 








Supplementary Figure S7: Assessment of HSCR candidate genes in zebrafish. 
 
Distribution of HuC positive migratory enteric neuronal precursors in 6 dpf zebrafish 
embryos from controls and knockdown of HSCR candidate gene orthologs. Genes with a 
statistically significant reduction in cell numbers are indicated by an asterisk. Note that 
there are two ednrb zebrafish orthologs but only ednrbb was significant in these assays; 







Supplementary Figure S8: Comparison of depth of sequencing at HSCR genes and rare 





Supplementary Figure S9: Overview of all case and comparison group samples analyzed, 






Supplementary Figure S10: Variance vs. mean of deleterious SNV counts per gene in 190 
controls over 10,000 sampling events; N=4,027 genes with >= 1 del SNVs in both 190 








It is well established that autism spectrum disorder (ASD) has a male skewed sex 
ratio of ~4:1 (Fombonne, 2003; Loomes et al., 2017). This higher disease prevalence in 
males can be explained by a multiple threshold liability model in which females are 
protected by not yet understood sex-biased mechanisms that raise their liability 
threshold for clinical disease. Under this model, females are affected only when they 
harbor a greater number of and or higher severity autism risk variants than their male 
counterparts. Consistent with this model, dizygotic twins of female probands show 
higher autism concordance than those of male probands (Robinson et al., 2013), and 
children with one affected older sibling have a higher recurrence risk when the older 
sibling is female than male – 7% for female and 3.7% for male older siblings (Jorde et al., 
1991). Werling and Geschwind (2015) showed that the difference in recurrence risk is 
more pronounced between siblings having at least two affected older siblings – 44.3% 
for female-containing and 30.4% for male-only proband pairs. They further showed that 
a shorter inter-birth interval increases recurrence risk specifically in male-only families, 
indicating greater environmental risk for male-only families. This supports a stronger 
genetic basis for disease in female-containing families. In simplex families, it has been 
directly shown that affected females harbor more CNVs and more novel single 
nucleotide variants (SNVs) affecting autosomal, brain-expressed genes (Jacquemont et 




simplex families, because such families are the most common type. To study the high 
recurrence risk in affected females, we undertook genetic characterization of autism risk 
in multiplex families containing two or more female children severely affected with 
autism, or FEMFs. 
Our further requirements for inclusion beyond female sex, that disease be 
severe and that the families be multiplex, further increases the recurrence risk in such 
families (Turner et al., 2015). This increased recurrence risk should correspond either to 
an increased number of autism contributive variants in the FEMF probands or to a 
greater average risk conferred by each variant present or both. This increased genetic 
risk in FEMFs is inherited from unaffected parents but its effect is owing to the 
combination of variants in the affected offspring. In Hirschsprung’s disease, another 
multifactorial neurodevelopmental disorder with a similar male-skewed sex ratio, a 
positive relationship has been observed between membership in the same three 
recurrence risk classes represented by FEMFs (female sex, severe disease, and familial 
disease) and the proportion of individuals with coding variants discovered in the major 
risk gene (RET) (Emison et al., 2010). This supports our assumption that there is a higher 
burden of more damaging variants in FEMFs probands, and, specifically, that variants 
affecting the coding sequence, and, therefore, the function of proteins, are more 
common in FEMFs than in autism families having lower recurrence risk. A preliminary 
genetic-cum-functional study in FEMFs resulted in the identification of CTNND2, and the 
suggestion of CYFIP1, as autism risk genes (Turner et al., 2015). This success 




Hirschsprung disease, presented in the preceding chapter, represents a case in 
which we have been able to assign large components of the genetic risk for a 
multifactorial disorder to several well characterized genes and pathways whose role in 
the disorder is relatively well understood. Autism spectrum disorder (ASD), on the other 
hand, represents a case in which there are many known risk genes but where the 
inherited contributions of these genes to risk for the disorder and the roles of these 
genes within the disorder are still not fully characterized. This is in part because genetic 
studies of autism have focused on gene discovery rather than understanding the basis 
for high familial risk. Many of the largest and most successful gene discovery studies 
have focused on simplex families, in which familial liability is low. Indeed, such families 
are expected to be enriched for de novo variation contributive to autism, which is 
relatively easy to identify and interpret (Iossifov et al., 2014; O’Roak et al., 2012; 
Sanders et al., 2012, 2015; Satterstrom et al., 2020). While these studies have provided 
valuable insights into genes disrupted in autism, understanding the contribution of de 
novo variation does not immediately lend itself to understanding autism’s high familial 
risk. 
Through our study of exome sequencing on 99 such FEMFs, we sought to 
characterize the contributions of rare coding variation in known and novel autism risk 
genes within these high recurrence risk families and to determine whether genetic risk 
in these families is caused by the same or a different set of genes from those that have 






4.2.1 Cohort ascertainment and description 
 
The female-enriched multiplex family (FEMF) cohort we studied consists of 416 
exome sequenced individuals from 99 nuclear families with the following characteristics: 
at least two female children affected with autism spectrum disorder under DSM-5 
criteria and at least one affected child (either male or female) having a diagnosis of 
autistic disorder under DSM-4 on the basis of both the Autism Diagnostic Interview 
Revised (ADIR) and Autism Diagnostic Observation Schedule (ADOS). The criterion that 
at least one affected child have a diagnosis of autistic disorder (a more narrowly defined 
and severe disorder compared to the autism spectrum as a whole) is how we ensured 
that we were selecting families with severely affected children, characterized by 
increased recurrence risk. These families were identified through a search of the Autism 
Genetics Resource Exchange and National Institute of Mental Health Autism Genetics 
databases. DNA samples were obtained for a total of 420 individuals from 100 families 
that met the inclusion criteria, though one family was later found to be duplicated and 
exome sequencing of one individual failed, as detailed in Quality Control. 
4.2.2 Exome sequencing methods 
 
Exome capture was performed on the 420 FEMF samples using the Agilent 44Mb 
Broad Version 2 capture kit, and all libraries were sequenced with 76bp paired-end 
Illumina sequencing. All sequencing, data preprocessing, and variant calling was 




and small (<50bp) insertions and deletions (Indels) was performed on a combined call-
set including the 420 FEMF samples and 371 non-Finnish European ancestry controls 
(comparable to FEMFs samples in capture and sequencing protocols) drawn from Nation 
Institute of Mental Health (NIMH) neuropsychiatric controls. Variant calls were made 
using the GATK Haplotype Caller in GATK version 3.1 (McKenna et al., 2010). Initial 
filtering of variants was done using the Variant Quality Score Recalibration (VQSR) 
method within GATK, which is based on detection of known variant sites. For SNVs, 
HapMap3.3 and Omni2.5 were used as training sites with HapMap3.3 used as the truth 
set. For VQSR of Indels, a set of curated Indels 
(Mills_and_1000G_gold_standard.indels.b37.vcf) that comprise the GATK resource 
bundle were used as both a training and truth set. In filtering of called variants, SNPs 
and Indel variants up to the 99.9% Truth Sensitivity tranche (0.1% false negative rate) 
were retained, in order to have sufficient sensitivity to discover novel variants in the 
FEMF samples. Sequencing failed in one sample leaving 419 samples: averaged across 
samples, 87% of capture targets were sequenced at a depth of at least 20x. 
 Only genotypes with PHRED-scaled quality score  20 and sequencing depth  
10 were used  for analyses, except in Mendelian gene filtering, where any genotype 
based on five or more reads were considered in order to provide more complete 
information about variant transmission in families where depth was variable across 
individuals. For enrichment and association testing, variants were only included in 





4.2.3 Variant annotation and classification 
 
Variants in FEMFs and in the 370 controls were primarily annotated using 
ANNOVAR (Wang et al., 2010).  Frequency annotations included frequency in 1000 
Genomes super-populations, all Exome Aggregation Consortium (ExAC) subpopulations, 
and all Exome Variant Server (EVS) subpopulations. Gene annotations used the refGene 
track downloaded from the UCSC genome browser. Multiple conservation and 
functional scores were included in annotation of all variants (including PHRED-scaled 
CADD Scores), but Indels were separately annotated for pathogenicity using SIFT Indel 
(Hu & Ng, 2013). 
 For testing the contributions of known genes (identified through de novo loss of 
function in low recurrence risk families) to autism risk in FEMFs, we used two definitions 
of what constituted a damaging variant: loss-of-function (LOF) variants only and all 
putatively damaging variants. For both classes of variants, a minor allele frequency 
(MAF) of ≤ 0.1% was required across all ExAC, EVS, and 1KG samples. LOF variants were 
defined as nonsense variants and frameshifting Indels predicted by SIFT Indel to be 
damaging. The more inclusive set of damaging variants also included missense and ± 2 
bp splice sites both with PHRED-scaled CADD score ≥ 20 and non-frameshifting indels 
categorized by SIFT Indel as damaging. 
 For association-based tests, we used all putatively damaging variants, as defined 
above, except that we used a more inclusive MAF cutoff of 1% rather than 0.1% used to 




for genes previously identified through de novo LOF because we expected true 
damaging variants in these genes to be highly penetrant in the heterozygous state and 
sought to exclude less damaging variation from these large and sometimes missense 
tolerant genes in that analysis. However, for gene discovery in a relatively small cohort, 
we wished to allow for less penetrant and recessive alleles present in the general 
population at higher frequency and which we expect to disproportionately contribute to 
the higher heritable risk in FEMFs. 
 Prior to our family-based analyses in FEMFs, the GATK genotype refinement 
workflow was used to identify and exclude variants with apparent de novo inheritance 
in the 77 FEMFs, where both parents had been successfully exome sequenced, as these 
variants do not contribute to heritable autism and because of the high false positive rate 
for this class of called variants. This was not done for association-based analyses 
because such a step could not be taken for available exome sequenced controls. 
4.2.4 Sample quality control 
 
First, ancestry and the relatedness between the FEMFs samples were 
investigated using the SNPRelate package in R (Zheng et al., 2012). For ancestry 
estimation, 260 samples collected through the 1000 Genomes Project, 10 from each of 
the 26 populations sampled, were combined with 100 independent FEMFs probands for 
principal components analysis (PCA) using only autosomal variants with MAF ≥ 5% and 
missingness ≤ 1% across all samples, linkage disequilibrium (LD) trimmed using an r2 




sequenced and called using the same protocols as the FEMFs samples at the Broad 
Institute, though they were called separately. Based on plots of the first three principal 
components (Figure 1), the FEMFs cohort was found to consist of primarily European 
ancestry families in addition to 9 families with Native American, 4 with African and 3 
with East Asian ancestry as well. 
 As a check on identity and relationships within our cohort, we also used 
SNPRelate to compute pairwise relatedness coefficients for all individuals in the FEMFs 
cohort, using the same variant filtering criteria as for PCA. We found that two of the 100 
families were, in fact, a single family reported in both databases with different cell ID’s, 
lowering our total number of families to 99. We also identified 5 samples reported as 
being from affected females that were clearly mislabeled. Four of these samples had no 
relationships to their reported families and were male (as determined by average depth 
of coverage on the Y chromosome). The other sample was a duplicate of an unaffected 
male sibling. Fortunately, there was at least one additional affected individual for each 
of the families containing mislabeled samples. Additionally, 4 additional sets of 
monozygotic twins were identified within these families, and 10 that had been reported 
in the NIMH family information were confirmed. 13 of these sets of identical twins are 
comprised of concordantly affected females and the other is comprised of concordantly 
affected males.  We removed the 9 anomalous samples to obtain a sequenced FEMFs 
cohort of 410 samples from 99 families.  This includes 187 affected females, 22 affected 
males, 24 male and female unaffected siblings, 95 mothers, and 82 fathers. Both parents 




4.2.5 Recalling genotypes of FEMFs for comparison to SSC 
 
 In order to compare rare coding variant-based genetic risk between the FEMF 
population characterized by high recurrence risk and a collection of low recurrence risk 
families, we recalled the FEMF exome data and 1,506 mixed ancestry control exomes 
using the same analysis pipeline used for the SSC (Simons Simplex Collection) Total 
Recall Project (Krumm et al., 2015), restricting our attention to capture regions common 
across the different sequencing kits used. Unfortunately, no comparison of burden 
could be made because of quality and analytic inconsistencies within the SSC exome 
data across its contributing sequencing centers. To expand somewhat upon these 
inconsistencies, the number of called variants (both rare and common) in the SSC 
exome calling data varied widely, in stark contrast to fairly consistent numbers of called 
variants across FEMFs and control exome calls made with the same calling pipeline. The 
number of called variants moreover, could not be explained by depth of sequencing, the 
rate at which sequencing reads could be mapped, or differences in capture efficiency. 
Interestingly, when SSC sequencing was recalled by us (using what was, based on 
published methods, the same pipeline, more sites were called, and the data were more 
consistent. Thus, it is possible that recalling the entire SSC exome dataset would have 
allowed for comparison to FEMFs. This computational task was not, however, feasible 
for us, and we proceeded with only our planned analyses that compared FEMFs to 




4.2.6 Test of pathogenic variant enrichment in previously reported autism 
genes 
 
We first wished to confirm the relevance of previously identified autism genes in 
this high-risk cohort, and, therefore, tested enrichment of deleterious variants within 99 
independent probands from each family. For this analysis we used a high confidence set 
of 28 genes (estimated FDR of 0.01), reported in Sanders et al. 2015, that were drawn 
from several large-scale autism genomic studies. The total number of LOF and all 
deleterious variants and the number of genes hit by these two classes of variants within 
the 28 high confidence autism genes were counted across the 99 probands. FEMF 
enrichment for variation in these two classes was determined by comparing the number 
of variants within these two classes in FEMFs to those that occurred in 99 control 
individuals randomly chosen from the 370 NIMH controls based on 10,000 samples 
taken with replacement. 
4.2.7 Rare variant association testing 
 
In order to detect genes enriched for rare damaging variation in FEMFs, we 
estimated the probability (P value) of finding as many or a greater number of distinct 
pathogenic alleles in each gene among 99 FEMF probands, compared to the number of 
distinct pathogenic alleles (as defined previously) expected on the basis of the 
frequency of such alleles in 114,704 individuals from the gnomAD database version 
2.1.1 (Karczewski et al., 2020) not ascertained on the basis of any neurological disorder. 




annotated and filter gnomAD variants in the genes we tested as we had previously 
annotated FEMF variants. However, we did not test all genes. In order to increase our 
power to find autism genes, we reduced the genes that we tested for association to 
those where we might reasonably expect loss of function to result in a high fitness 
effect, which would be expected for highly penetrant autism genes. Therefore, we 
tested for association in only those genes having a gnomAD pNull intolerance score < 
0.5 (i.e., those genes that are classified as having >50% chance of being essential, based 
on LOF frequency in healthy controls) in order to exclude genes unlikely to have severe, 
high penetrance phenotypes from consideration. We further restricted our attention to 
only those genes harboring 1 pathogenic allele in both FEMF probands and healthy 
controls in the gnomAD database so that we only tested genes for which we could 
reasonably estimate the frequency of such variants in both groups. In order to exclude 
spurious associations resulting from batch-specific calling artifacts, we also excluded 
genes that had two of more pathogenic alleles in 370 jointly called European ancestry 
controls. A total of 2,204 genes met all of the criteria set out above and were tested for 
association. 
As the first stage in this association test, we ascertained the observed number of 
distinct pathogenic alleles (d0) in the 99 probands (a random variable d). We then 
estimated the expected number of distinct alleles by simulating 99 diploid genotypes for 
each gene, assigning gnomAD alleles to individuals on the basis of their allele frequency. 
We did this with 10,000 replications, using the mean (?̅?) as the expected rate of distinct 




α = Prob {d ≥ do|?̅?}, assuming d to be Poisson distributed. We used a Bonferroni 
correction to account for the 2,204 tests performed such that we considered only genes 
having α values at or below 2.3 x 10-5 (equivalent to a threshold of 0.05) to represent 
significant associations. 
4.2.8 Family-based filtering to identify high penetrance genes 
 
 In order to identify potential cases of high penetrance recessive inheritance in 
FEMFs, pathogenic alleles were defined as they were for rare variant association testing. 
Genes were considered to be potentially recessively inherited within a family if all 
affected family members had homozygous or compound heterozygous genotypes and 
all unaffected family members had at least one reference allele. 
 In order to identify potential cases of incompletely penetrant dominant 
inheritance in FEMFs, we established a stricter definition of allele pathogenicity. First, in 
order to exclude variant-calling artifacts, we only retained alleles observed no more 
than once in 370 jointly called NIMH controls. Second, we used a more stringent MAF 
cutoff of 0.1% across control databases compared to the 1% cutoff used for recessive 
gene filtering. Third, we used a more stringent PHRED-scaled CADD score threshold of 
29 to further restrict variants to those that are expected to be the most damaging. In 
order to consider only those genes expected to have dominant disease inheritance, we 
also restricted genes to those having a pLI > 0.9, indicating intolerance of single copy 





 In order to test the significance of our dominant and recessive gene findings in 
FEMFs, we counted instances of potential dominant or recessive inheritance (counting 
each apparent dominant or recessive gene separately even if it occurred in the same 
family as another gene), and we used a computer simulation-based approach to 
determine whether there was enrichment in FEMFs compared to what we would 
expect, given the parental genotypes for putatively pathogenic alleles. For this test it 
was necessary to restrict our comparison to the 77 families for which both parental 
genotypes were available. We also performed a separate test restricted to only the 73 
families for which at least two affecteds had been sequenced. 
4.3 Results 
 
4.3.1 Enrichment in previously reported autism genes 
 
For both LOF and all deleterious variants, significant FEMF enrichment was 
observed for the number of genes hit (P = 0.029 for LOF and P = 0.012 for deleterious 
variants, respectively) but not for the total number of variants. These results are shown 
in Figure 2. While some of the genes identified as autism genes on the basis of de novo 
association are depleted for variation in controls, others among these genes harbor a 
great number of rare damaging alleles. Thus, both FEMF probands and controls may 
harbor deleterious variants driven by a few genes, but variation in less tolerant genes in 
FEMFs drive enrichment in the number of genes affected. 





 Among the 2,204 genes tested for rare variant association in FEMFs, none were 
significantly associated with autism after multiple testing correction. Association 
information on the top 50 associated genes can be found in Table 1, alongside 
information on the transmission of variants in those genes to additional affected 
individuals within FEMFs (beyond the probands, on whom the association is based). 46 
of the top 50 associated genes have 2 or more distinct pathogenic alleles in FEMFs, and 
many are supported by multiple transmissions to affected siblings, providing a basis for 
stratification of autism candidate genes. 
4.3.3 Family-based filtering 
 
After filtering families to identify those where autism might be explained by 
recessive inheritance, there were seven genes that showed potential compound 
heterozygous inheritance in eight families, of which five families have two sequenced 
parents. No families had putatively damaging variants inherited in a manner consistent 
with homozygous recessive inheritance. 
After filtering to identify families where autism might be explained by 
incompletely penetrant dominant inheritance, we found at least one candidate 
dominant gene in 42 of the 77 families (with a total of 68 instances) in which both 
parents and at least one affected child had been exome sequenced. These findings are 
summarized in Table 3. 
 In our computer simulations to determine whether putatively damaging 




inheritance more than would be expected by chance, damaging alleles were not 




 The question whether genes discovered through de novo mutation make 
contributions to autism in families characterized by high heritable risk for autism is an 
important one. It is necessary to know the extent to which variation in these genes 
contribute to genetic risk in different family types in order to use them meaningfully in 
counselling high risk families. There is also a question as to whether the same variation 
that causes autism in males also causes autism in females – it may be that the reason 
fewer females are affected by autism is that females are only susceptible to certain 
autism genes. This study indicates that at least some of the 28 genes discovered through 
de novo mutation in primarily male containing families do make a significant 
contribution to autism genetic risk in high risk female containing families (Sanders et al., 
2015). Larger studies that are capable of comparing the impact of these de novo risk 
genes between female and male containing families will ultimately be necessary to 
quantify the extent to which these genes make contributions. We were unable to 
attempt this for lack of comparable datasets for individuals at lower risk, but the high 
rate at which autism families are now being whole genome sequenced will allow these 




 While we failed to detect significant autism associated genes in FEMFs owing to, 
presumably, the relatively small size of the FEMF cohort and the complexity of autism 
genetics, it is quite possible that many of the genes most associated with autism in our 
study contribute to the phenotypes observed in these families, but, in the absence of 
the ability to functionally validate these genes or to confirm their association in an 
independent dataset, it is not possible to know for certain. Our previous success in 
identifying bona fide risk genes using association in a relatively small cohort combined 
with functional validation both in Chapter 3 of this dissertation and in previous studies 
of FEMFs (Turner et al., 2015) shows the value of sub-significant associations paired with 
functional validation. This is not surprising given that most genes contributing to a 
disease do so in only a small fraction of families. The advantage of looking at a smaller 
cohort like FEMFs with extreme heritable risk compared to identifying autism genes in a 
larger cohort at low genetic risk is that the discovery of genes is likely to be of greater 
benefit to affected families, and genes discovered may better contribute to our 
understanding of the high heritability of autism. Therefore, studies in cohorts such as 
this one are of great value, though success requires functional assays and independent 
validation. 
 There are many well characterized “Mendelian” disorders that contribute to 
autism risk, and, as we have discussed in previous chapters, these disorders have 
variable phenotypic features and penetrance. Betancur (2011) identified more than one 
hundred syndromic disorders with which autism is associated. While we were not able 




developmental disorders with autism associations are a potentially fruitful area to 
investigate in order to understand autism in some families. Many of these known genes 
have accompanying syndromic features, some of which may be subtle and others not 
universal (canonical). We did not have access to detailed phenotyping of the individuals 
in the FEMF cohort, as we did for families described in Chapter 2 of this thesis, and this 
was likely contributory. Given that we found many potential instances of Mendelian 
inheritance in these families, it is well worth the additional effort in collecting families to 
achieve the kind of phenotypic depth that would allow both genetic and phenotypic 
associations to be used to understand the genes underlying autism or other 
neurodevelopmental disorders. 
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4.5 Chapter 4 Tables: 
 
Table 1: Top 50 autism associated genes from rare variant testing (no significant hits) 
aCounts for 99 probands, 370 NIMH controls, and the gnomAD mean all refer to the 
number of distinct pathogenic alleles. bCounts of genotyped affected siblings of proband 
are totaled across the different proband carriers of damaging variants in each gene and 
“affected sibling carriers” indicates the number of those additional genotyped affecteds 
harboring the same pathogenic allele as their proband sibling. 

















X NAA10 2 0 9.16E-05 0.01 1 0 
2 HNRNPA3 2 0 3.50E-04 0.03 2 1 
12 SELPLG 2 1 3.96E-04 0.03 4 0 
2 STAT4 5 2 8.21E-04 0.71 6 2 
10 PIK3AP1 3 2 8.35E-04 0.18 3 1 
20 EIF2S2 2 0 1.00E-03 0.05 2 2 
X MAP7D3 2 2 1.27E-03 0.05 2 0 
9 TTF1 2 0 1.31E-03 0.05 3 1 
13 ZDHHC20 2 0 1.49E-03 0.06 2 1 
2 PIGF 2 1 1.59E-03 0.06 1 0 
5 SLC12A2 3 0 1.78E-03 0.23 3 1 
12 CD27 2 1 1.87E-03 0.06 2 0 
6 ZKSCAN8 2 1 1.99E-03 0.06 2 0 
X DIAPH2 2 2 1.99E-03 0.06 1 1 
12 TBC1D15 3 0 2.19E-03 0.25 4 1 
2 SCN3A 4 0 2.22E-03 0.53 3 3 
4 CCNI 2 0 2.39E-03 0.07 0 0 
9 LINGO2 2 0 2.47E-03 0.07 2 1 
6 HLA-A 2 2 2.50E-03 0.07 1 0 
15 BMF 2 2 2.62E-03 0.07 3 1 
17 RHBDL3 3 1 3.08E-03 0.28 4 3 
6 DLK2 3 1 3.13E-03 0.29 5 3 
15 ZNF280D 2 1 3.28E-03 0.08 2 1 
12 LGR5 4 0 4.05E-03 0.63 5 0 
5 IK 2 1 4.20E-03 0.09 4 0 
4 C4orf27 2 2 4.22E-03 0.09 2 0 
6 BCLAF1 2 2 4.25E-03 0.10 3 2 




19 LIM2 2 0 4.42E-03 0.10 2 2 
3 ZNF502 2 1 4.50E-03 0.10 3 2 
22 TIMP3 2 1 4.66E-03 0.10 3 2 
1 HIPK1 3 0 4.71E-03 0.33 4 4 
1 LEPROT 2 1 4.77E-03 0.10 3 0 
X TNMD 2 1 4.82E-03 0.10 1 1 
21 C2CD2 3 0 4.97E-03 0.34 4 3 
14 SNW1 2 0 5.30E-03 0.11 3 1 
17 IKZF3 2 0 5.52E-03 0.11 3 3 
8 PARP10 3 0 6.42E-03 0.37 2 1 
12 SRRM4 2 1 6.81E-03 0.12 2 1 
15 SLC27A2 3 1 7.29E-03 0.39 5 3 
5 CHD1 3 1 7.57E-03 0.39 5 4 
6 CDSN 1 0 7.77E-03 0.01 1 0 
2 PPP3R1 1 2 8.07E-03 0.01 2 0 
2 RAPGEF4 4 2 8.08E-03 0.77 5 2 
3 CRYGS 2 1 8.47E-03 0.14 1 1 
1 STRIP1 3 2 8.50E-03 0.41 4 2 
9 GDA 2 0 8.52E-03 0.14 2 1 
4 OCIAD2 1 1 8.66E-03 0.01 1 0 
3 LHFPL4 1 0 8.86E-03 0.01 2 0 






Table 2: Instances of compound heterozygous inheritance 
Variants and genotypes for FEMFs are given with respect to the amino acid sequence change. Families indicated with an * have only 
one genotyped parent. aThese two variants are inherited on the same haplotype. b “-“ indicates that the variant was not present in 
the database. 
Family Gene Transcript Variant Father Mother Proband #1 Proband #2 Unaffected #1 CADD ExAC MAFb 
50002 EPPK1 NM_031308 
G2270S G/G G/Sa ambiguous G/S G/G 36 - 
A2259S A/A A/Sa A/S A/S A/A 20.8 0.0009 
A1900V A/V A/A A/V A/V A/V 33 0.001 
50004 LRBA NM_001199282 
N815S N/N N/S N/S N/S unknown 24.7 0.0018 
F598C F/C F/F F/C F/C unknown 25.4 - 
50016 PRDM2 NM_001007257 
S1158N S/N S/S S/N S/N - 21.8 - 
1056del E/E E/- E/- E/- - NA 0.0041 
50032* PREX1 NM_020820 
R1589K R/R unknown R/K unknown unknown 31 0.0009 
D794N D/N unknown D/N unknown unknown 21 0.0008 
50044 KIAA0430 NM_001184998 
S1620F S/F S/S S/F S/F - 34 0.0042 
G4R G/G G/R G/R G/R - 28 0.0041 
50058* EPPK1 NM_031308 
E2295K E/E unknown E/K E/K E/E 35 0.0002 
V1902fs V/fs unknown V/fs V/fs V/fs NA 0.0006 
50078 SLC16A5 NM_001271765 
S343T S/S S/T S/T unknown S/S 22.7 0.00005511 
37del F/- F/F F/- unknown F/- NA 0.0001 
50093* FBXO25 NM_012173 
D163H unknown D/D D/H D/H - 21.8 0.0002 






Table 3: Instances of possible dominant inheritance in FEMFs 
As in Table 2, variants and genotypes for FEMFs are given with respect to the amino acid sequence change. Note that there are 
several instances in which dominant multigenic inheritance is a possibility. aThis is a start-loss Indel variant. 















CADD ExAC MAF 
50000 
ATAD2 NM_014109 I527V I/V I/I I/V unknown - - - - 31 1.17E-05 
ATRN NM_001207047 A1063T A/T A/A A/T unknown - - - - 35 1.10E-05 
FBN1 NM_000138 G1482S G/S G/G G/S unknown - - - - 36 2.20E-05 
50004 
JARID2 NM_001267040 R655Q R/Q R/R R/Q R/Q - - unknown - 36 - 
TULP4 NM_020245 A1516V A/V A/A A/V A/V - - unknown - 33 0.0003 
50005 MAP3K4 NM_001301072 D279N D/N D/D D/N D/N - - - - 34 4.44E-05 
50007 
IPO7 NM_006391 R252Q R/R R/Q R/Q R/Q - - R/R - 31 2.21E-05 
SIK3 NM_001281749 V173I V/I V/V V/I V/I - - V/V - 32 - 
TSC2 NM_001318831 R439Q R/Q R/R R/Q R/Q - - R/R - 34 4.48E-05 
50013 HEATR1 NM_018072 S28C S/S S/C - S/C - - - - 33 - 
50016 HEATR1 NM_018072 P1397S P/P P/S P/S P/S - - - - 31 3.33E-05 
50018 
ADNP NM_001282532 A1017Gfs A/fs A/A - A/fs - - - - NA 1.11E-05 
EIF3G NM_003755 G76S G/S G/G - G/S - - - - 33 - 
MPRIP NM_001364716 D562N D/D D/N - D/N - - - - 35 3.31E-05 
50020 
CLUH NM_001366661 R1067C R/R R/C R/C R/C - - unknown - 29.1 1.26E-05 
NMT1 NM_021079 G205S G/G G/S G/S G/S - - unknown - 32 5.51E-05 
PPP1R13B NM_015316 R380I R/I R/R R/I R/I - - unknown - 32 0.0002 
50024 TLN1 NM_006289 A2013T A/T A/A A/T A/T A/T A/T unknown unknown 31 0.0005 
50025 HMGCS1 NM_001324219 V162A V/V V/A - V/A V/A - V/V - 29.6 2.21E-05 
50027 
HERC2 NM_004667 G2974R G/G G/R G/R unknown - - - - 29.1 - 
HGF NM_000601 G186E G/G G/E G/E unknown - - - - 33 2.21E-05 




50030 BICD2 NM_001003800 E157Rfs E/fs E/E E/fs E/fs E/fs - - - NA - 
50036 
GMPS NM_003875 P612L P/P P/L P/L P/L - - P/P - 34 - 
KDM4A NM_014663 K301R K/K K/R K/R K/R - - K/K - 35 1.10E-05 
50037 ARIH2 NM_001317334 V37M V/M V/V V/M V/M - - V/V - 29.2 1.10E-05 
50041 
KIAA0368 NM_001363756 V1726E V/V V/E V/E V/E - - V/V V/V 32 - 
LRP12 NM_001135703 S598X S/X S/S S/X S/X - - S/S S/S 39 - 
50042 
CLOCK NM_004898 Q626del Q/del Q/Q Q/del Q/del Q/del - - - NA 6.62E-05 
TSHZ1 NM_001308210 P342Afs P/fs P/P P/fs P/fs P/fs - - - NA - 
50043 SNX2 NM_003100 F74L F/F F/L F/L F/L unknown - F/F - 33 - 
50044 CAMK2G NM_001367524 G14W G/G G/W G/W G/W unknown - - - 31 1.10E-05 
50046 CSNK1D NM_001363749 S114Vfs S/S S/fs S/fs S/fs - - - - NA - 
50053 MKL1 NM_001282660 E126K E/K E/E E/K E/K - - - - 37 1.10E-05 
50059 HNRNPA3 NM_001330247 K112del K/K K/del K/del - - - - - NA - 
50062 WDFY3 NM_014991 R3166X R/X R/R R/X R/X unknown - - - 52 - 
50064 CLK2 NM_001294339 R267Q R/Q R/R R/Q R/Q R/Q - unknown unknown 34 - 
50065 
CHD2 NM_001271 R1678Q R/Q R/R R/Q R/Q - - - - 33 9.92E-05 
DOCK9 NM_001130049 K715E K/K K/E K/E K/E - - - - 29.9 1.12E-05 
50067 TNRC6B NM_015088 S1537G S/G S/S S/G S/G - - S/S - 32 - 
50068 AHCTF1 NM_001323342 R209H R/R R/H R/H R/H - - - - 32 1.10E-05 
50071 
C6orf136 NM_001109938 P47L P/L P/P P/L P/L - - unknown unknown 37 - 
DYRK1A NM_001347723 R14C R/R R/C R/C R/C - - unknown unknown 32 4.41E-05 
NR6A1 NM_001278546 S181L S/S S/L S/L S/L - - unknown unknown 36 - 
SYT11 NM_152280 S63del S/del S/S S/del S/del - - unknown unknown NA - 
50072 COPB1 NM_001144061 E464V E/E E/V E/V E/V - - unknown - 33 - 
50076 
ANKRD11 NM_001256183 K1012del K/del K/K K/del K/del - - - - NA 8.82E-05 
MYH9 NM_002473 E1225K E/E E/K E/K E/K - - - - 35 1.10E-05 
TMEM201 NM_001010866 P85L P/P P/L P/L P/L - - - - 29 2.32E-05 




50077 APC2 NM_001351273 E189K E/K E/E E/K E/K - - unknown - 36 1.55E-05 
50078 
EFNB2 NM_004093 N282del N/del N/N N/del unknown - - N/N - NA 0.0001 
TRIO NM_007118 E2656K E/K E/E E/K unknown - - E/E - 35 1.10E-05 
50080 MLXIP NM_014938 P201L P/L P/P P/L P/L - - - - 35 0.0001 
50083 
CTPS1 NM_001905 A129V A/A A/V A/V A/V - - - - 34 0.0001 
IGF2R NM_000876 R1325H R/H R/R R/H R/H - - - - 33 1.10E-05 
50085 TRRAP NM_003496 K1839M K/M K/K K/M K/M K/M - - - 30 - 
50089 
DOPEY1 NM_001199942 R944H R/R R/H R/H R/H - - unknown - 31 0.0001 
NAV2 NM_001111018 S224N S/S S/N S/N S/N - - unknown - 32 0.0004 
50090 RELN NM_005045 A1568V A/A A/V A/V A/V - - - - 32 2.21E-05 
50091 LRP2 NM_004525 R2181H R/H R/R R/H R/H - - - - 33 7.78E-05 
50094 
KIF1B NM_001365951 A219S A/A A/S A/S A/S - - unknown - 36 - 
LAMC1 NM_002293 A333V A/V A/A A/V A/V - - unknown - 29.1 1.10E-05 
WNT3A NM_033131 S181Hfs S/fs S/S S/fs S/fs - - unknown - NA 2.55E-05 
50095 GATAD2B NM_020699 E23K E/E E/K E/K E/K - - unknown - 30 6.62E-05 
50097 HIPK1 NM_198269 M1?a M/M M/? M/? M/? M/? - - - 35 - 
50100 
DNAJA2 NM_005880 R388H R/R R/H R/H R/H - - unknown - 33 0.0002 




Table 4: Test for over-transmission of putatively damaging parental alleles 
Here we compared the number of instances of possible dominant and recessive 
inheritance to simulations based on random segregation of alleles. a Here quads 
indicates families in which there are two genotyped parents and two genotyped 
affected siblings. bNote that there are two additional instances of possible dominant 
inheritance used for comparison to simulated counts – beyond those presented in 
Tables 2 and 3; these two additional instances were removed after the protein 
annotation was found to be incorrect, but these variants were used for comparison to 
simulations in order to ensure comparability between the FEMF observed and simulated 





Instances in 77 
FEMF trios 
Instances in 73 
FEMF quadsa 
In 10,000 simulations 
of 77 trios 
In 10,000 simulations 
of 73 quads 
Recessive 5 4 
p = 0.79 (mean = 
6.49, SD = 2.43) 
p = 0.74  (mean = 
4.96, SD  =2.17) 
Dominant 70a 58a 
p = 0.62 (mean = 
71.86, SD = 7.32) 
p = 0.70  (mean = 




4.6 Chapter 4 Figures: 
Figure 1: Determining ancestry of FEMFs through PCA  
 FEMFs are plotted alongside NIMH controls and 1KG African ancestry (AFR), 
Native American admixed ancestry (AMR), East Asian ancestry (ASN), 




Figure 2: FEMFs have rare damaging variants affecting a greater than expected number 
of genes previously associated with autism 
The number of genes and distinct variants affecting those genes are plotted for 10,000 
individuals sampled from 370 NIMH controls with replacement, with the genes and 
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